SEARCH
検索詳細
南野 佳英医学部附属病院 肝胆膵外科助教
研究活動情報
■ 受賞- 2023年 膵臓学会, 第17回膵臓学会国際優秀演題賞
- 2018年 日本経腸静脈栄養学, Young Doctors Award国内外の国際的学術賞
- 2015年 Asia Pacific Digestive Week, Young Investigator’s Award国内外の国際的学術賞
- 2015年 国際膵臓学会, International Association of Pancreatology Grant国内外の国際的学術賞
- BACKGROUND: Resection of pancreatic ductal adenocarcinoma (PDAC) after prior esophagectomy for esophageal cancer is technically demanding and its oncologic value is unclear. We evaluated the peri-operative safety and long-term survival after pancreatectomy for PDAC in this setting. METHODS: All patients undergoing pancreatectomy for PDAC at Kobe University Hospital (2017-2024) were reviewed. Outcomes in patients with previous esophagectomy for esophageal cancer were compared with those in patients undergoing contemporaneous resectable PDAC without such history. Primary endpoints were postoperative morbidity/mortality and overall survival. RESULTS: Of 415 pancreatectomies, nine (2.2%) had a history of esophagectomy for esophageal cancer (pancreaticoduodenectomy five; distal pancreatectomy four). Preservation of the gastrointestinal-conduit vessels was achieved in seven patients; two required right gastroepiploic artery and vein reconstruction. Major morbidity occurred in one patient (11.1%); there was no 90-day mortality and no conduit-related complication. However, only three patients (33.3%) received adjuvant chemotherapy. Median overall survival was significantly shorter in post-esophagectomy patients (n = 9) than in controls (n = 249) (8.4 vs. 41.7 months, p = 0.001). Survival after pancreaticoduodenectomy was especially poor (7.4 vs. 47.2 months, p < 0.001), whereas outcomes after distal pancreatectomy did not differ (16.4 vs. 38.9 months, p = 0.781). CONCLUSIONS: Pancreatectomy after esophagectomy can be performed safely, even with minimally invasive techniques, yet long-term survival remains dismal, particularly after pancreaticoduodenectomy. Careful patient selection with specific attention to the feasibility of delivering perioperative chemotherapy may be required to improve outcomes in this highly selected cohort.2026年02月, Annals of surgical oncology, 33(2) (2), 918 - 924, 英語, 国際誌研究論文（学術雑誌）
- PURPOSE: The Global Leadership Initiative on Malnutrition (GLIM) criteria, proposed in 2018, provide universal diagnostic standards for malnutrition, a known risk factor for postoperative complications in patients with various cancers. However, its impact on surgery for biliary tract cancer (BTC) remains unclear. This study evaluates the relationship between GLIM-defined malnutrition and postoperative complications after resection for BTC. METHODS: The subjects of this retrospective study were patients who underwent pancreaticoduodenectomy or major hepatectomy with extrahepatic bile duct resection for BTC between January, 2013 and December, 2021. The comprehensive complication index (CCI), an indicator of postoperative complications, was calculated based on the total number and severity of postoperative complications. RESULTS: GLIM-defined malnutrition was diagnosed in143 (71.1%) of the total 201 patients. The median CCI was significantly higher in the GLIM-defined malnutrition group than in the non-malnutrition group (37.2 vs. 28.3; P < 0.001). Multivariate logistic regression analysis revealed that GLIM-defined malnutrition (odds ratio 2.87 [95% confidence interval 1.38-5.96], P = 0.005) and intraoperative blood loss > 1,000 mL (odds ratio 3.77 [95% confidence interval 1.06-13.47], P = 0.041) were independent predictors of high morbidity (CCI ≥ 37.1). CONCLUSION: Preoperative GLIM-defined malnutrition was closely associated with increased postoperative complications in patients who underwent resection for BTC.2025年11月, Surgery today, 55(11) (11), 1598 - 1608, 英語, 国内誌研究論文（学術雑誌）
- AIM: Regarding the resectability of pancreatic adenocarcinoma (PDAC), not only anatomical factors but also biological and conditional factors have come to be considered. This study examined the impact of the Global Leadership Initiative on Malnutrition (GLIM) criteria on prognosis after resection of anatomically resectable PDAC. METHODS: The medical records of consecutive patients who underwent resection for resectable PDAC between January 1, 2014, and December 31, 2022, were retrospectively reviewed. Patients were classified as normal, moderately, or severely malnourished according to the GLIM criteria. RESULTS: In total, 194 patients were included in the analysis. According to the GLIM criteria, 61 (31.4%), 49 (25.2%), and 84 (42.3%) patients were normal, moderately, and severely malnourished, respectively. Patients with malnutrition had shorter overall, recurrence-free, and disease-specific survival (OS, RFS, and DSS) than normal patients (OS, normal vs. moderate, p = 0.015; normal vs. severe, p < 0.001; RFS, normal vs. moderate p = 0.012, normal vs. severe, p < 0.001; DSS, normal vs. moderate, p = 0.023; normal vs. severe, p < 0.001). In multivariate analysis regarding OS using all factors, moderate or severe malnutrition according to the GLIM criteria (p = 0.007), performance status (p = 0.086), preoperative diabetes (p = 0.017), tumor diameter ≥ 3 cm (p = 0.002), lymph node metastasis (p < 0.001), and postoperative adjuvant therapy (p = 0.027) were independent prognostic factors. In multivariate analysis using preoperative factors, malnutrition according to the GLIM criteria remained a significant prognostic factor (p = 0.003). CONCLUSION: The GLIM criteria are effective prognostic predictors in patients with resectable PDAC undergoing upfront surgery. Preoperative nutritional assessment using these criteria may contribute to determining treatment plans for resectable PDAC.2025年11月, Annals of gastroenterological surgery, 9(6) (6), 1351 - 1361, 英語, 国内誌研究論文（学術雑誌）
- PURPOSE: We aimed to investigate the differences in surgical difficulty between laparoscopic partial liver resections of segments 7 and 8. METHODS: We analyzed 173 patients who underwent partial liver resections of segments 7 or 8 between 2010 and 2022 at two institutions. We investigated differences in the surgical outcomes of each procedure using propensity score matching. We compared these outcomes with those of open partial liver resections for segments 7 and 8 to determine whether the differences were unique to the laparoscopic approach. RESULTS: Thirty and 54 patients underwent laparoscopic partial liver resections of segments 7 and 8. In the matched cohort (22 in each group), the operation time was significantly longer (377 vs. 278 min, P = 0.020) and the proportion of postoperative complications significantly higher in segment 7 (27% vs. 0%, P = 0.008). Forty-one and 48 patients underwent open partial liver resections of segments 7 and 8, respectively. There were no significant differences in the surgical outcomes between the segments in the matched cohort (20 in each group). CONCLUSIONS: Laparoscopic partial liver resections of segment 7 may be more challenging than that of segment 8. This difference in difficulty was not observed in open partial liver resections.2025年10月, Surgery today, 55(10) (10), 1383 - 1392, 英語, 国内誌研究論文（学術雑誌）
- BackgroundThis study aimed to evaluate the impact of postoperative complications on early recurrence (ER) after pancreaticoduodenectomy (PD) for biliary tract cancer (BTC).MethodsPatients who underwent PD for BTC between 2009 and 2022 were enrolled in this study. Postoperative complications were assessed using the comprehensive complication index (CCI), calculated by summing all the complications. The optimal CCI cutoff value for predicting ER was selected based on the minimum P value from the chi-square test. ER was defined as recurrence within 12 months of resection. Risk factors for ER were identified using multivariate analysis.ResultsA total of 118 patients were analyzed. ER was observed in 34 (28.8 %) patients, indicating a significantly poorer prognosis than those without ER (log-rank, P < .001). No significant differences were observed in the primary tumor site or pathological features between the low CCI (<42.6) and high CCI (≥42.6) groups. The incidence of ER was significantly higher in the high CCI group than in the low CCI group (50.0% vs 24.0%, P = .015). Multivariate analysis revealed that high CCI (odds ratio [OR] 4.43, 95% confidence interval [CI] 1.41-13.97, P = .011) and R1 resection (OR 4.88, 95% CI 1.43-16.70, P = .012) were independent risk factors for ER.DiscussionPostoperative complications after PD for BTC were found to be independent risk factors for ER.2025年08月, The American surgeon, 31348251368282 - 31348251368282, 英語, 国際誌研究論文（学術雑誌）
- Portal annular pancreas (PAP) is an uncommon anomaly in which the pancreatic parenchyma surrounds the portal or superior mesenteric vein. An adequate operative approach is necessary to prevent clinically relevant postoperative pancreatic fistula after pancreaticoduodenectomy for PAP. We herein report a case of robotic pancreaticoduodenectomy for PAP. In PAP, dissection of the retroportal parenchyma is the most important aspect of surgery. Adequate retraction of the portal system using vessel loops allows for a safe dissection and transection of the retroportal parenchyma. The robotic approach has some advantages for dissecting the retroportal parenchyma. The magnified three-dimensional view helps the surgeon distinguish the nerve plexus from the pancreatic parenchyma. The caudal view allows for direct dissection of the retroportal parenchyma from the superior mesenteric artery. Dissection can easily be performed using articulated forceps. Owing to these advantages, robotic pancreaticoduodenectomy can be safely performed for PAP.2025年07月, Surgery today, 55(7) (7), 1004 - 1007, 英語, 国内誌研究論文（学術雑誌）
- BACKGROUND: Partial pancreatectomies for intraductal papillary mucinous neoplasms (IPMN) often leave a dilated main pancreatic duct (MPD). However, its impact on the development of remnant pancreatic lesions is unknown. METHODS: Medical records of consecutive patients who underwent partial pancreatectomy for noninvasive or microinvasive IPMN with dilated MPD on preoperative imaging between April 2007 and March 2023 at two tertiary referral centers in Japan were retrospectively reviewed. A dilated remnant MPD (DRM) was defined as an MPD diameter of the expected remnant pancreas of ≥5 mm. The clinically significant remnant pancreatic lesion (CSRPL) was defined as a remnant pancreatic lesion which requires intervention. RESULTS: A total of 172 patients (106 males and 66 females) were analyzed. Preoperatively, 132 patients (76.7 %) had mixed-type IPMN and 40 (23.1 %) had main duct IPMN. Among them, 16 patients (9.3 %) had CSRPL at 1569 days (median; range, 120-5503 days) after the initial surgery. In the preoperative imaging analysis, 104 patients (60.5 %) had DRM. The univariate analysis revealed that high-grade or micro-invasive pathology (p = 0.013) was significantly associated with CSRPL, whereas DRM was inversely associated with CSRPL (p = 0.021). The multivariate analysis revealed that the trends of DRM (p = 0.002) and high-grade/micro-invasive pathology (p = 0.003) remained significant. CONCLUSIONS: Leaving a dilated MPD did not increase but instead inversely associated with the incidence of CSRPL after IPMN resection. It was suggested that preserving the pancreas, including the dilated MPD, is oncologically safe if the lesion of interest can be resected.2025年05月, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 25(3) (3), 440 - 449, 英語, 国際誌研究論文（学術雑誌）
- AIM: Evidence regarding the reliability of endoscopic ultrasound-guided tissue acquisition (EUS-TA) for assessing histological proliferation and WHO grading of small (≤20 mm) pancreatic neuroendocrine tumors (PanNETs) is limited. METHODS: In this multicenter retrospective study, we analyzed data from 122 patients with small PanNETs who underwent EUS-TA followed by surgical resection between 2006 and 2022. We compared the histopathological proliferation assessment and WHO grading between preoperative EUS-TA and surgical definitive specimens. RESULTS: Among the 122 patients with small PanNETs (80% with surgical definitive WHO grade G1 and 20% with G2), EUS-TA histology identified neuroendocrine tumors in 101 (83%) patients and provided WHO grading in 85 (70%) patients. Histopathological WHO grading for EUS-TA was concordant with surgical definitive grading in 86% (73/85) of cases, overstaged in 4% (3/85), and understaged in 11% (9/85). Moderate, severe, and fatal adverse events associated with EUS-TA, as classified by the lexicon, were not reported in this cohort. CONCLUSION: EUS-TA is a reliable method for assessing histopathological proliferation and WHO grading of small PanNETs. However, grading discordance may occur, and a risk-benefit evaluation on a per-patient basis is recommended.2025年03月, Annals of gastroenterological surgery, 9(2) (2), 339 - 346, 英語, 国内誌研究論文（学術雑誌）
- Allogeneic islet transplantation becomes a viable option for patients with unstable type 1 diabetes. However, considering the huge number of patients with type 1 diabetes, human donor shortage is a serious issue. To overcome the donor shortage issue, xenotransplantation is an attractive option. In fact, clinical islet xenotransplantation has been conducted since 1990s. The first clinical trial was performed using fetal pigs and demonstrated the porcine pancreatic tissue could survive in human body with immunosuppressive strategies. To scale up the islet production, Canadian group established a method for islet isolation from neonatal pigs. Their method has been used for clinical islet xenotransplantation in New Zealand, Russian, Mexico, Argentina, and China. Recently Korean group published a clinical protocol for islet xenotransplantation using adult pigs. For the next generation of islet xenotransplantation, gene-modified pigs were created. Especially "superislets" created by Belgian group demonstrated promising preclinical outcomes. With advanced donor pigs, islet xenotransplantation might become a suitable treatment for the majority of type 1 diabetic patients.2025年, Cell transplantation, 34, 9636897251332532 - 9636897251332532, 英語, 国際誌研究論文（学術雑誌）
- INTRODUCTION: Portal vein (PV) and splenic vein (SV) stenosis are known complications of pancreatoduodenectomy (PD) and often lead to portal hypertension. PV stenosis extending to the SV confluence can result in sinistral portal hypertension (SPH), characterized by gastrointestinal varices and splenomegaly in the presence of normal liver function. There is no standardized treatment strategy for SPH following PD. CASE PRESENTATION: A 42-year-old female underwent robot-assisted PD for a pancreatic neuroendocrine tumor without immediate PV complications. Postoperatively, the patient experienced fluid retention; however, this did not pose a problem, and no therapeutic intervention was necessary. Two months later, imaging revealed PV stenosis and SV obstruction. Eleven months after surgery, the patient presented with melena, and imaging confirmed the presence of gastroesophageal varices with severe PV stenosis and complete SV obstruction. Endoscopic variceal ligation was performed, and the hemodynamic status of the portal system was assessed using computed tomography during arterial portography (CTAP). CTAP showed communication between the superior mesenteric vein and the SV via the middle colic vein. Therefore, we decided to perform PV stenting. The stent was successfully placed, resulting in a significant improvement in the esophageal varices. The patient was discharged on postoperative day 4, receiving anticoagulant therapy, with no further complications. CONCLUSIONS: This case demonstrates the efficacy of PV stenting after careful hemodynamic assessment in a patient who developed SPH due to PV stenosis and SV obstruction following PD.2025年, Surgical case reports, 11(1) (1), 英語, 国内誌研究論文（学術雑誌）
- BACKGROUND/AIM: Biliary tract cancers (BTCs) have poor prognoses, with limited curative options beyond surgical resection. Adjuvant S-1 chemotherapy has shown survival benefits in Japanese patients undergoing resection for BTC. However, prognostic factors influencing survival in these patients remain uncertain. In this study, we aimed to investigate the efficacy of preoperative nutritional status using the Global Leadership Initiative on Malnutrition (GLIM) criteria as a prognostic factor in patients receiving adjuvant S-1 chemotherapy for BTC. PATIENTS AND METHODS: In this retrospective study, excluding intrahepatic cholangiocarcinoma, we evaluated 58 patients who underwent curative surgery for BTC at Kobe University from 2013 to 2022, followed by adjuvant S-1 chemotherapy. Nutritional status was classified by GLIM criteria into normal/moderate and severe malnutrition groups. Overall (OS) and recurrence-free (RFS) survival were analyzed using Kaplan-Meier and Cox proportional hazards models. RESULTS: Of the 58 patients, 3.4% had no malnutrition, 72.5% had moderate malnutrition, and 24.1% had severe malnutrition. Patients with severe malnutrition had significantly worse 5-year OS (24.7% vs. 52.5%, p=0.0014) and RFS (34.3% vs. 52.0%, p=0.0066). Severe malnutrition was an independent prognostic factor for poorer OS (hazard ratio=3.40, 95% confidence interval=1.46-7.94; p=0.0047) and RFS (hazard ratio=2.48, 95% confidence interval=1.07-5.76; p=0.035). No significant difference in S-1 completion rates was observed. CONCLUSION: Severe malnutrition, as defined by GLIM criteria, is a poor prognostic factor in patients with BTCs undergoing adjuvant S-1 chemotherapy.2025年, Cancer diagnosis & prognosis, 5(5) (5), 557 - 565, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: Systemic inflammation and altered metabolism are essential hallmarks of cancer. We hypothesized that the rapid turnover protein transthyretin (TTR) (half-life: 2-3 days), compared with the conventional marker albumin (21 days), better reflects the inflammatory/metabolic dynamics of pancreatic ductal adenocarcinoma (PDAC) after neoadjuvant therapy (NAT) and is a useful prognostic marker. METHODS: Serum TTR and albumin levels were measured in 104 consecutive post-NAT PDAC patients before curative resection. The associations of preoperative TTR and albumin levels with overall survival (OS) after pancreatectomy were retrospectively analyzed. RESULTS: The mean (SD) TTR and albumin levels were 21.6 (6.4) mg/dL (normal range: ≥22.0 mg/dL) and 3.9 (0.55) g/dL. A low (<22.0 mg/dL) post-NAT TTR level was associated with an advanced tumor stage and higher CEA and CRP levels. Patients with low TTR levels showed significantly worse OS compared with normal levels (3-year OS 39 % vs. 54 %, P = 0.037), although albumin levels did not. We modified prognostic biomarkers of systemic inflammation/metabolism, such as GPS, PNI, and CONUT scores, using the serum TTR instead of albumin level and successfully showed that modified scores were better associated with OS compared with original scores using serum albumin level. CONCLUSIONS: Our data suggest that the TTR level is a promising prognostic biomarker for PDAC patients after NAT.2024年09月, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 24(6) (6), 917 - 924, 英語, 国際誌研究論文（学術雑誌）
- PURPOSE: The technical difficulties of laparoscopic liver resection (LLR) are greatly associated with the location of liver tumors. Since segment 8 (S8) contains a wide area, the difficulty of LLR for S8 tumors may vary depending on the location within the segment, such as the ventral (S8v) and dorsal (S8d) area, but the difference is unclear. METHODS: We retrospectively investigated 30 patients who underwent primary laparoscopic partial liver resection for liver tumors in S8 at Kobe University Hospital between January 2018 and June 2023. RESULTS: Thirteen and 17 patients underwent LLR for S8v and S8d, respectively. The operation time was significantly longer (S8v 203[135-259] vs. S8d 261[186-415] min, P = 0.002) and the amount of blood loss was significantly higher (10[10-150] vs. 10[10-200] mL, P = 0.034) in the S8d group than in the S8v group. No significant differences were observed in postoperative complications or postoperative length of hospital stay. Additionally, intraoperative findings revealed that the rate at which the case performed partial liver mobilization in the S8d group was higher (2[15.4%] vs. 8[47.1%], P = 0.060) and the median parenchymal transection time of the S8d group was longer (102[27-148] vs. 129[37-175] min, P = 0.097) than those in the S8v group, but there were no significant differences. CONCLUSION: The safety of LLR for the S8d was comparable to that of LLR for S8v, although LLR for S8d resulted in longer operative time and more blood loss. THE TRIAL REGISTRATION NUMBER: B230165 (approved at December 26, 2023).2024年08月, Langenbeck's archives of surgery, 409(1) (1), 243 - 243, 英語, 国際誌研究論文（学術雑誌）
- PURPOSE: The impact of postoperative bile leak on the prognosis of patients with hepatocellular carcinoma who underwent liver resection is controversial. This study aimed to investigate the prognostic impact of bile leak for patients with hepatocellular carcinoma who underwent liver resection. METHODS: Patients with hepatocellular carcinoma who underwent liver resection between 2009 and 2019 at Kobe University Hospital and Hyogo Cancer Center were included. After propensity score matching between the bile leak and no bile leak groups, differences in 5-year recurrence-free and overall survival rates were evaluated using the Kaplan-Meier method. RESULTS: A total of 781 patients, including 43 with postoperative bile leak, were analyzed. In the matched cohort, 40 patients were included in each group. The 5-year recurrence-free survival rates after liver resection were 35% and 32% for the bile leak and no bile leak groups, respectively (P = 0.857). The 5-year overall survival rates were 44% and 54% for the bile leak and no bile leak groups, respectively (P = 0.216). CONCLUSION: Overall, bile leak may not have a profound negative impact on the prognosis of patients with hepatocellular carcinoma who have undergone liver resection.2024年07月, Langenbeck's archives of surgery, 409(1) (1), 233 - 233, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND/AIM: This study aimed to evaluate the utility of the albumin-bilirubin grade for predicting the prognosis after repeat liver resection for patients with recurrent hepatocellular carcinoma. PATIENTS AND METHODS: Ninety patients with intrahepatic recurrent hepatocellular carcinoma who underwent repeat liver resection at our institution between 2005 and 2019 were retrospectively analyzed. Cox proportional-hazards regression models evaluated independent preoperative prognostic factors, including the albumin-bilirubin grade. Prognosis differences between patients with albumin-bilirubin grades 1 and 2 were analyzed using the Kaplan-Meier method. RESULTS: Cox proportional-hazards regression analysis revealed that albumin-bilirubin grade 2 (p=0.003) and early recurrence within one year from the initial surgery (p=0.001) were independently associated with poor recurrence-free survival, and albumin-bilirubin grade 2 (p=0.020) was independently associated with poor overall survival. The five-year recurrence-free (31% and 17%, respectively) and overall (86% and 60%, respectively) survival rates after repeat liver resection for patients with albumin-bilirubin grades 1 and 2 were significantly different between groups (both p=0.003). CONCLUSION: The albumin-bilirubin grade is useful for preoperatively predicting favorable survival rates after repeat liver resection for patients with recurrent hepatocellular carcinoma. Patients with an albumin-bilirubin grade 1 are better candidates for surgical treatment of recurrent hepatocellular carcinoma.2024年05月, Anticancer research, 44(5) (5), 2031 - 2038, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: Drainage fluid amylase (DFA) is useful for predicting clinically relevant postoperative pancreatic fistula (CR-POPF) after distal pancreatectomy (DP). However, difference in optimal cutoff value of DFA for predicting CR-POPF between open DP (ODP) and laparoscopic DP (LDP) has not been investigated. This study aimed to identify the optimal cutoff values of DFA for predicting CR-POPF after ODP and LDP. METHODS: Data for 294 patients (ODP, n = 127; LDP, n = 167) undergoing DP at Kobe University Hospital between 2010 and 2021 were reviewed. Propensity score matching was performed to minimize treatment selection bias. Receiver operating characteristic (ROC) analysis was performed to determine the optimal cutoff values of DFA for predicting CR-POPF for ODP and LDP. Logistic regression analysis for CR-POPF was performed to investigate the diagnostic value of DFA on postoperative day (POD) three with identified cutoff value. RESULTS: In the matched cohort, CR-POPF rates were 24.7% and 7.9% after ODP and LDP, respectively. DFA on POD one was significantly lower after ODP than after LDP (2263 U/L vs 4243 U/L, p < 0.001), while the difference was not significant on POD three (543 U/L vs 1221 U/L, p = 0.171). ROC analysis revealed that the optimal cutoff value of DFA on POD one and three for predicting CR-POPF were different between ODP and LDP (ODP, 3697 U/L on POD one, 1114 U/L on POD three; LDP, 10564 U/L on POD one, 6020 U/L on POD three). Multivariate analysis showed that DFA on POD three with identified cutoff value was the independent predictor for CR-POPF both for ODP and LDP. CONCLUSIONS: DFA on POD three is an independent predictor for CR-POPF after both ODP and LDP. However, the optimal cutoff value for it is significantly higher after LDP than after ODP. Optimal threshold of DFA for drain removal may be different between ODP and LDP.2024年03月, Surgical endoscopy, 38(5) (5), 2699 - 2708, 英語, 国際誌研究論文（学術雑誌）
- 金原出版(株), 2024年03月, 手術, 78(4) (4), 535 - 544, 日本語
- INTRODUCTION: Surgical resection is considered an effective cure for biliary tract cancer (BTC); however, the prognosis is unsatisfactory despite improved surgical techniques and perioperative management. The recurrence rate remains high even after curative resection. The efficacy of adjuvant chemotherapy in pancreatic and gastric cancers has been previously reported, and the feasibility of adjuvant therapy with S-1 has recently been reported in patients with resected BTC. We aimed to retrospectively investigate the effects of adjuvant chemotherapy with S-1 on resected advanced BTC. METHODS: We included data from 438 BTC patients who underwent resection between 2001 and 2020. After excluding patients with pTis-pT1 (n = 112) and other exclusion criteria, 266 patients were included in the analysis. RESULTS: After propensity score matching, 48 patients received S-1 adjuvant chemotherapy (S-1 group), and 48 patients received non-S1 adjuvant chemotherapy or underwent surgery alone (Non-S-1 group). The patients in the S-1 group had significantly better overall survival (OS) than those in the non-S-1 group (MST 51 vs 37 months, hazard ratio [HR]:.54, 95% confidence interval [CI]:.30-.98, P = .04). The S-1 group had a significantly better recurrence-free survival (RFS) than the non-S-1 group (94 vs 21 months, HR: .57, 95% CI: .33-.97, P = .03). Subgroup analyses for OS and RFS exhibited the benefits of S-1 in patients aged <75 years and in patients with primary sites of extrahepatic and perineural invasion and curability of R0. DISCUSSION: S-1 adjuvant therapy is promising for improving the postoperative survival of patients with resected advanced BTC, positive nerve invasion, and R0 resection.2024年01月, The American surgeon, 90(6) (6), 31348241227188 - 31348241227188, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: Venous thromboembolism (VTE) is a potentially fatal complication of hepatectomy. The use of postoperative prophylactic anticoagulation in patients who have undergone hepatectomy is controversial because of the risk of postoperative bleeding. Therefore, we hypothesized that monitoring plasma D-dimer could be useful in the early diagnosis of VTE after hepatectomy. AIM: To evaluate the utility of monitoring plasma D-dimer levels in the early diagnosis of VTE after hepatectomy. METHODS: The medical records of patients who underwent hepatectomy at our institution between January 2017 and December 2020 were retrospectively analyzed. Patients were divided into two groups according to whether or not they developed VTE after hepatectomy, as diagnosed by contrast-enhanced computed tomography and/or ultrasonography of the lower extremities. Clinicopathological factors, including demographic data and perioperative D-dimer values, were compared between the two groups. Receiver operating characteristic curve analysis was performed to determine the D-dimer cutoff value. Univariate and multivariate analyses were performed using logistic regression analysis to identify significant predictors. RESULTS: In total, 234 patients who underwent hepatectomy were, of whom (5.6%) were diagnosed with VTE following hepatectomy. A comparison between the two groups showed significant differences in operative time (529 vs 403 min, P = 0.0274) and blood loss (530 vs 138 mL, P = 0.0067). The D-dimer levels on postoperative days (POD) 1, 3, 5, 7 were significantly higher in the VTE group than in the non-VTE group. In the multivariate analysis, intraoperative blood loss of > 275 mL [odds ratio (OR) = 5.32, 95% confidence interval (CI): 1.05-27.0, P = 0.044] and plasma D-dimer levels on POD 5 ≥ 21 μg/mL (OR = 10.1, 95%CI: 2.04-50.1, P = 0.0046) were independent risk factors for VTE after hepatectomy. CONCLUSION: Monitoring of plasma D-dimer levels after hepatectomy is useful for early diagnosis of VTE and may avoid routine prophylactic anticoagulation in the postoperative period.2024年01月, World journal of clinical cases, 12(2) (2), 276 - 284, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: Although diabetes after total pancreatectomy and islet autotransplantation (TP-IAT) is one of the biggest concerns for TP-IAT recipients and physicians, reliable prediction of post-TP-IAT glycemic control remains unestablished. This study was conducted to identify early predictors of insulin independence and goal glycemic control by hemoglobin A1c (HbA1c) ≤ 6.5% after TP-IAT. METHODS: In this single-center, retrospective study, patients who underwent TP-IAT (n = 227) were reviewed for simple metabolic markers or surrogate indices of β-cell function obtained 3 mo after TP-IAT as part of standard clinical testing. Long-term metabolic success was defined as (1) insulin independence and (2) HbA1c ≤ 6.5% 1, 3, and 5 y after TP-IAT. Single- and multivariate modeling used 3-mo markers to predict successful outcomes. RESULTS: Of the 227 recipients, median age 31 y, 30% male, 1 y after TP-IAT insulin independence, and HbA1c ≤ 6.5% were present in 39.6% and 72.5%, respectively. In single-predictor analyses, most of the metabolic markers successfully discriminated between those attaining and not attaining metabolic goals. Using the best model selected by random forests analysis, we accurately predicted 1-y insulin independence and goal HbA1c control in 77.3% and 86.4% of the patients, respectively. A simpler "clinically feasible" model using only transplanted islet dose and BETA-2 score allowed easier prediction at a small accuracy loss (74.1% and 82.9%, respectively). CONCLUSIONS: Metabolic testing measures performed 3 mo after TP-IAT were highly associated with later diabetes outcomes and provided a reliable prediction model, giving valuable prognostic insight early after TP-IAT and help to identify recipients who require early intervention.2024年01月, Transplantation direct, 10(1) (1), e1561, 英語, 国際誌研究論文（学術雑誌）
- Pancreatic islets contain beta cells which produce insulin based on the blood glucose levels resulting in tight control of blood glucose levels. In type 1 diabetic patients, most of the beta cells are destroyed, therefore, pharmaceutical insulin injection is mandatory to avoid diabetes-related illness and death. Even with recent advanced insulin therapy, hypoglycemia is a critical limiting factor to control blood glucose levels. There is no doubt that hypoglycemia can be fatal. Allogeneic islet transplantation can prevent severe hypoglycemia and provide excellent blood glucose control. On the other hand, allograft donor shortage is the major issue. To overcome donor shortage, xenograft has been used and shown safety and efficacy. Recently stem-cell-derived beta cells are clinically applied. In this chapter, the history and current status of allogenic islet transplantation and future scope are described.IntechOpen, 2023年12月, Allogeneic Islet Transplantation and Future, 英語論文集(書籍)内論文
- (株)癌と化学療法社, 2023年12月, 癌と化学療法, 50(13) (13), 1534 - 1536, 日本語
- BACKGROUND: Postoperative cholangitis is a common complication of pancreaticoduodenectomy. Frequent cholangitis impairs patients' quality of life after pancreaticoduodenectomy. However, the risk factors for recurrence of cholangitis remain unclear. Hence, this retrospective study aimed to identify risk factors for recurrence of cholangitis after pancreaticoduodenectomy. METHODS: The medical records of patients who underwent pancreaticoduodenectomy between 2015 and 2019 in our institution were retrospectively reviewed. At least two episodes of cholangitis a year after pancreaticoduodenectomy were defined as 'recurrence of cholangitis' in the present study. Univariate and multivariate analyses were performed. RESULTS: The recurrence of cholangitis occurred in 40 of 207 patients (19.3%). Multivariate analysis revealed that internal stent (external, RR: 2.16, P = 0.026; none, RR: 4.76, P = 0.011), firm pancreas (RR: 2.61, P = 0.021), constipation (RR: 3.49, P = 0.008), and postoperative total bilirubin>1.7 mg/dL (RR: 2.94, P = 0.006) were risk factors of recurrence of cholangitis. Among patients with internal stents (n = 54), those with remnant stents beyond 5 months had more frequent recurrence of cholangitis (≥5 months, 75%; <5 months, 30%). CONCLUSIONS: Internal stents, firm pancreas, constipation, and postoperative high bilirubin levels are risk factors for cholangitis recurrence after pancreaticoduodenectomy. In addition, the long-term implantation of internal stents may trigger cholangitis recurrence.2023年10月, World journal of surgery, 47(10) (10), 2499 - 2506, 英語, 国際誌研究論文（学術雑誌）
- 日本膵・胆管合流異常研究会, 2023年09月, 日本膵・胆管合流異常研究会プロシーディングス, 46, 30 - 30, 日本語
- BACKGROUND: Long-term outcomes and prognostic factors of proton radiotherapy for locally advanced pancreatic cancer (LAPC) in the body and tail are still unknown. The aim of this study was to determine the prognostic factors after proton radiotherapy in a large group of patients with LAPC in the body and tail. METHODS: The medical records of 200 patients with LAPC in the body and tail who underwent proton radiotherapy between February 2009 and January 2021 at the Hyogo Ion Beam Medical Center were retrospectively reviewed to identify prognostic factors that contribute to long-term survival. RESULTS: The overall survival rate at 1- and 2-year after PT was 69.6% and 35.4% with a median overall survival of 18.4 months. The 1- and 2-year local progression-free, and progression-free survival rates were 84.3% and 68.0%, and 44.3% and 19.4%, respectively. In multivariate analysis, superior mesenteric artery (SMA) invasion (SMA only invasion vs. celiac artery only invasion; P = 0.049: SMA and celiac artery invasion vs. celiac artery only invasion; P = 0.017), carbohydrate antigen 19-9 (CA 19-9) level ≥ 231.9 U/mL (P = 0.001), anterior peripancreatic invasion (P = 0.006), and incomplete scheduled concurrent chemotherapy (P = 0.009) were statistically significant prognostic factors for overall survival. There was no significant difference in local progression-free survival; however, distant metastasis-free survival was statistically worse in patients with prognostic factors than in those without. CONCLUSIONS: Proton radiotherapy for LAPC in the body and tail may be a valuable multidisciplinary treatment option. Patients with SMA invasion, higher pre-proton radiotherapy serum CA 19-9 level, anterior peripancreatic invasion, or incomplete scheduled concurrent chemotherapy had worse overall survival because of worse distant metastasis-free survival, suggesting that distant metastases have a significant impact on overall survival in such patients. TRIAL REGISTRATION: Retrospectively registered.2023年08月, Radiation oncology (London, England), 18(1) (1), 131 - 131, 英語, 国際誌研究論文（学術雑誌）
- Transarterial chemoembolization (TACE) is performed for pancreatic neuroendocrine tumor (PanNEN) liver metastases; however, the safety and efficacy of TACE procedures, especially for patients who have undergone previous pancreatic surgery, have not been established. We reviewed 48 TACE procedures (1-6 procedures/patient) performed on 11 patients with PanNEN liver metastases, including 16 TACE procedures (4-6 procedures/patient) for 3 patients with a history of biliary-enteric anastomosis. The overall tumor objective response rate was 94%. The incidence of Clavien‒Dindo grade ≥ 2 complications was 1/16 (6%) and 1/32 (3%), and the median time to untreatable progression was 31 (14-41) and 27 (2-60) months among patients with and without a history of biliary-enteric anastomosis, respectively. Although validation is needed in future studies, our experiences have shown that TACE treatment is a viable treatment option for PanNEN liver metastases, even after biliary-enteric anastomosis with experienced teams and careful patient follow-up.2023年06月, Surgery today, 53(12) (12), 1396 - 1400, 英語, 国内誌研究論文（学術雑誌）
- BACKGROUND: Less intra-abdominal adhesions are expected following laparoscopic surgery. Although an initial laparoscopic approach for primary liver tumors may have advantages in patients who require repeat hepatectomies for recurrent liver tumors, this has not been sufficiently investigated. METHODS: Patients who underwent repeat hepatectomies for recurrent liver tumors at our hospital between 2010 and 2022 were retrospectively analyzed. Of 127 patients, 76 underwent laparoscopic repeat hepatectomy (LRH), of whom 34 patients initially underwent laparoscopic hepatectomy (L-LRH) and 42, open hepatectomy (O-LRH). Fifty-one patients underwent open hepatectomy as both the initial and second operation (O-ORH). We analyzed surgical outcomes between L-LRH and O-LRH groups and between L-LRH and O-ORH groups using propensity-matching analysis for each pattern. RESULTS: Twenty-one patients each were included in L-LRH and O-LRH propensity-matched cohorts. The L-LRH group had a lower rate of postoperative complications than the O-LRH group (0 vs 19%, P = 0.036). When we compared surgical outcomes between L-LRH and O-ORH groups in another matched cohort with 18 patients in each group, in addition to the lower rate of postoperative complications, the L-LRH group had additional favorable surgical outcomes including shorter operation time and lower blood loss volume than the O-ORH group (291 vs 368 min, P = 0.037 and 10 vs 485 mL, P < 0.0001). CONCLUSIONS: An initial laparoscopic approach would be favorable for patients undergoing repeat hepatectomies, as it leads to lower risk of postoperative complications. Compared with O-ORH, the advantage of the laparoscopic approach may be enhanced when it is repeatedly adopted.2023年06月, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 27(8) (8), 1621 - 1631, 英語, 国際誌研究論文（学術雑誌）
- 2023年06月, Annals of surgical oncology, 30(9) (9), 5790 - 5791, 英語, 国際誌研究論文（学術雑誌）
- 2023年06月, Annals of surgical oncology, 30(6) (6), 3501 - 3502, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: Sarcopenia, defined as a loss of skeletal muscle mass and quality, is found in 30-65% of patients with pancreatic ductal adenocarcinoma (PDAC) at diagnosis, and is a poor prognostic factor. However, it is yet to be evaluated why sarcopenia is associated with poor prognosis. Therefore, this study elucidated the tumor characteristics of PDAC with sarcopenia, including driver gene alterations and tumor microenvironment. PATIENTS AND METHODS: We retrospectively analyzed 162 patients with PDAC who underwent pancreatic surgery between 2008 and 2017. We defined sarcopenia by measuring the skeletal muscle mass at the L3 level using preoperative computed tomography images and evaluated driver gene alteration (KRAS, TP53, CDKN2A/p16, and SMAD4) and tumor immune (CD4+, CD8+, and FOXP3+) and fibrosis status (stromal collagen). RESULTS: In localized-stage PDAC (stage ≤ IIa), overall survival (OS) and recurrence-free survival were significantly shorter in the sarcopenia group than in the non-sarcopenia group (2-year OS 89.7% versus 59.1%, P = 0.03; 2-year RFS 74.9% versus 50.0%, P = 0.02). Multivariate analysis revealed that sarcopenia was an independent poor prognostic factor in localized-stage PDAC. Additionally, tumor-infiltrating CD8+ T cells in the sarcopenia group were significantly less than in the non-sarcopenia group (P = 0.02). However, no difference was observed in driver gene alteration and fib.rotic status. These findings were not observed in advanced-stage PDAC (stage ≥ IIb). CONCLUSIONS: Sarcopenia was associated with a worse prognosis and decreased tumor-infiltrating CD8+ T cells in localized-stage PDAC. Sarcopenia may worsen a patient's prognosis by suppressing local tumor immunity.2023年05月, Annals of surgical oncology, 30(9) (9), 5776 - 5787, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND/AIM: Recently, the Global Leadership Initiative on Malnutrition (GLIM), which includes the world's leading clinical nutrition societies, proposed the first global diagnostic criteria for malnutrition. However, the association between malnutrition diagnosed by the GLIM criteria and prognosis in patients with resected extrahepatic cholangiocarcinoma (ECC) remains unknown. This study aimed to investigate the predictive validity of the GLIM criteria for the prognosis of patients with resected ECC. PATIENTS AND METHODS: Between 2000 and 2020, 166 patients who underwent curative-intent resection for ECC were retrospectively analyzed. Prognostic significance of preoperative malnutrition diagnosed by the GLIM criteria was investigated using a multivariate Cox proportional hazards model. RESULTS: Eighty-five (51.2%) and 46 (27.7%) patients were diagnosed with moderate and severe malnutrition, respectively. Increased malnutrition severity tended to be correlated with increased lymph node metastasis rate (p-for-trend=0.0381). The severe malnutrition group had worse 1-, 3-, and 5-year overall survival rates than the normal (without malnutrition) group (82.2% vs. 91.2%, 45.6% vs. 65.1%, 29.3% vs. 61.5%, respectively, p=0.0159). In multivariate analysis, preoperative severe malnutrition was an independent predictor for poor prognosis (hazard ratio=1.68, 95% confidence interval=1.06-2.66, p=0.0282), along with intraoperative blood loss >1,000 ml, lymph node metastasis, perineural invasion, and curability. CONCLUSION: Severe preoperative malnutrition diagnosed by the GLIM criteria was associated with poor prognosis in patients who underwent curative-intent resection for ECC.2023年05月, Anticancer research, 43(5) (5), 2299 - 2308, 英語, 国際誌研究論文（学術雑誌）
- 2023年03月, Annals of surgical oncology, 30(6) (6), 3503 - 3504, 英語, 国際誌研究論文（学術雑誌）
- 72歳女性。右季肋部痛を主訴に前医を受診し、右横隔膜原発の腫瘍を指摘され、精査加療目的で当院へ紹介となった。腹部CT検査では右横隔膜と連続した9cm大で、不均一な造影効果を伴う境界明瞭な腫瘤が認められた。また、腹部MRI検査ではT1強調画像にて筋組織と同程度の低信号ほか、T2強調画像にて高信号を呈する腫瘤が認められた。以上、これらの所見を踏まえて、針生検を施行したところ、採取されたのは壊死組織のみで、診断には困難であった。そこで、右横隔膜原発の腫瘍とみなし、開腹下に腫瘍を切除した結果、病理組織学的に右横隔膜腹腔側に発生したsolitary fibrous tumorと確定診断された。術後1年経過現在、無再発生存中である。兵庫県外科医会, 2023年03月, 兵庫県外科医会会誌, 57, 13 - 15, 日本語
- BACKGROUND: Optimal management of non-functioning pancreatic neuroendocrine tumors (PanNETs) ≤20 mm is controversial. The biological heterogeneity of these tumors poses challenges when deciding between resection and observation. METHODS: In this multicenter, retrospective cohort study, we analyzed all patients (n = 78) who underwent resection of non-functioning PanNETs ≤20 mm at three tertiary medical centers from 2004 to 2020 to assess the utility of preoperatively available radiological features and serological biomarkers of non-functioning PanNETs in choosing an optimal surgical indication. The radiological features included non-hyper-attenuation pattern on enhancement computed tomography (CT; hetero/hypo-attenuation) and main pancreatic duct (MPD) involvement, and serological biomarkers included elevation of serum elastase 1 and plasma chromogranin A (CgA) levels. RESULTS: Of all small non-functioning PanNETs, 5/78 (6%) had lymph node metastasis, 11/76 (14%) were WHO grade II, and 9/66 (14%) had microvascular invasion; 20/78 (26%) had at least one of these high-risk pathological factors. In the preoperative assessment, hetero/hypo-attenuation and MPD involvement were observed in 25/69 (36%) and 8/76 (11%), respectively. Elevated serum elastase 1 and plasma CgA levels were observed in 1/33 (3%) and 0/11 (0%) patients, respectively. On multivariate logistic regression analysis, hetero/hypo-attenuation (odds ratio [OR] 6.1, 95% confidence interval [CI] 1.7-22.2) and MPD involvement (OR 16.8, 95% CI 1.6-174.3) were significantly associated with the high-risk pathological factors. The combination of the two radiological worrisome features correctly predicted non-functioning PanNETs with high-risk pathological factors, with about 75% sensitivity, 79% specificity, and 78% accuracy. CONCLUSIONS: This combination of radiological worrisome features can accurately predict non-functioning PanNETs that may require resection.2023年02月, Annals of surgical oncology, 30(6) (6), 3493 - 3500, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: Bile leakage is a major complication after liver transplantation and remains as a significant source of morbidity and mortality. In 2011, the International Study Group of Liver Surgery (ISGLS) defined bile leakage as a drain/serum bilirubin ratio ≥3. However, to our knowledge there is no literature assessing serum and drain bilirubin concentrations after liver transplantation. The aim of this study was to describe the natural postoperative changes in serum and drain fluid bilirubin concentrations in patients after liver transplantation. METHODS: We included 32 patients who underwent liver transplantation at Kobe University Hospital from January 2007 to December 2020. We enrolled 34 living donors who had no complications as the control group. RESULTS: The recipient serum total/direct bilirubin concentration were higher compared with the donors from postoperative day (POD) 1 to 5 with a statistical difference (P < .05). The recipient drain/serum total bilirubin ratio was lower than donors on POD 3 (0.89 ± 0.07 vs 1.53 ± 0.07: P < .0001), which was also confirmed by the recipient drain/serum direct bilirubin ratio (0.64 ± 0.10 vs 1.18 ± 0.09: P < .0001). On POD 3, the drain fluid volume (647.38 ± 89.47 vs 113.43 ± 86.8 mL: P < .001) and serum total bilirubin concentration (6.73 ± 0.61 vs 1.23 ± 0.60 mg/dL: P < .001) was higher in the recipients than in donors. Categorized in 2 groups, the higher drain fluid volume and bilirubin concentration recipients showed lower drain/serum total bilirubin ratio compared with the other group (P = .03) CONCLUSION: The drain/serum bilirubin ratio in the transplanted patients could be calculated lower compared with the hepatectomy patients because of high drain fluid volume and hyperbilirubinemia. Great care should be taken when assessing the bile leakage in liver transplant recipients using the ISGLS definition.2023年01月, Transplantation proceedings, 55(1) (1), 184 - 190, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: Laparoscopic caudate lobe resection is a challenging procedure. Several researchers have reported the safety of laparoscopic liver resections;1.Transl Gastroenterol Hepatol. 1:56;2.Asian J Endosc Surg. 12:232-236;3.Ann Surg Oncol. 26:2980; however, a standardized procedure has not yet been established. Herein, we present a video showing laparoscopic Spiegel lobectomy in a patient with 6-cm hepatocellular carcinoma (HCC) using a novel approach. PATIENT AND METHODS: A 63-year-old man with a caudate lobe HCC was referred to our hospital. Computed tomography showed a 5 × 6 cm2 HCC located in the Spiegel lobe, which profoundly displaced the inferior vena cava (IVC) to the lower right side, and mobilization of the Spiegel lobe was considered difficult. To perform the dissection between the Siegel lobe and IVC safely, we performed parenchymal transection along the ventral side of the IVC initially. The Spiegel lobe was then dislocated to the left side of the IVC. We dissected the left lateral side of the IVC, including the proper hepatic vein draining the caudate lobe and the left IVC ligament with a safe operative field, and successfully removed the Spiegel lobe with large HCC. RESULTS: The operation time was 383 min. The blood loss was 10 mL. The patient was discharged on the seventh postoperative day without any complications. Histopathological examination revealed well-differentiated HCC with a negative surgical margin. CONCLUSIONS: Laparoscopic medial-to-lateral approach with initial parenchymal transection at the medial side of the Spiegel lobe followed by dissection of the left lateral side of the IVC is considered as a safe and effective procedure for large tumors in the Spiegel lobe.2023年01月, Annals of surgical oncology, 30(1) (1), 381 - 382, 英語, 国際誌研究論文（学術雑誌）
- 2023年01月, Annals of surgical oncology, 30(1) (1), 383 - 383, 英語, 国際誌研究論文（学術雑誌）
- INTRODUCTION: With the aging of the population in Japan, gallbladder cancer (GBC) in the elderly is increasing. However, the available clinical data are limited, and the optimal treatment is still controversial. The aim of this study was to evaluate the benefit of surgical resection in GBC patients ≥75 years of age. METHODS: A retrospective single center analysis of patients who had undergone surgical resection for GBC between 2000 and 2019 was carried out. Patients aged ≥75 years (elderly group, n = 24) or <75 years (younger group, n = 50) were compared. RESULTS: Both younger and elderly patients exhibited similar clinicopathological characteristics, but comorbidity in the latter was significantly greater, as was the frequency of less invasive surgery. Nonetheless, the incidence of postoperative complications was similar in elderly and younger patients. The proportion of patients receiving adjuvant chemotherapy was lower in the elderly. Overall survival of elderly and younger patients was not significantly different (65.0 vs 62.4% at 5 years, P = .600). In multivariate analysis, residual tumor status but not age was an independent prognostic factor. DISCUSSION: This study demonstrated that appropriate surgical treatment of elderly GBC patients was safe and effective, despite their having more comorbidities and lower rates of adjuvant chemotherapy than younger patients.2022年11月, The American surgeon, 89(12) (12), 31348221136570 - 31348221136570, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: Anatomic liver resection (ALR) has been established to eliminate the tumor-bearing hepatic region with preservation of the remnant liver volume for liver malignancies. Recently, laparoscopic ALR has been widely applied; however, there are few reports on laparoscopic segmentectomy 2. This study aimed to present the standardization of laparoscopic segmentectomy 2 with surgical outcomes. METHODS: This study included seven patients who underwent pure laparoscopic segmentectomy 2 by the Glissonean approach from January 2020 to December 2021. Four of them had hepatocellular carcinoma, two had colorectal liver metastasis, and one had hepatic angiomyolipoma, which was preoperatively diagnosed with hepatocellular carcinoma. In all patients, preoperative three-dimensional (3D) simulation images from dynamic CT were reconstructed using a 3D workstation. The layer between the hepatic parenchyma and the Glissonean pedicle of segment 2 (G2) was dissected to encircle the root of G2. After clamping or ligation of the G2, 2.5 mg of indocyanine green was injected intravenously to identify the boundaries between segments 2 and 3 with a negative staining method under near-infrared light. Parenchymal transection was performed from the caudal side to the cranial side according to the demarcation on the liver surface, and the left hepatic vein was exposed on the cut surface if possible. RESULTS: The mean operative time for all patients was 281 min. The mean blood loss was 37 mL, and no transfusion was necessary. Estimated liver resection volumes significantly correlated with actual liver resection volumes (r = 0.61, P = 0.035). After the operation, one patient presented with asymptomatic deep venous and pulmonary thrombosis, which was treated with anticoagulant therapy. The mean length of hospital stay was 8.9 days. CONCLUSION: Laparoscopic segmentectomy 2 by the Glissonean approach is a feasible and safe procedure with the preservation of the nontumor-bearing segment 3 for liver tumors in segment 2.2022年11月, Surgical endoscopy, 36(11) (11), 8600 - 8606, 英語, 国際誌研究論文（学術雑誌）
- 2022年09月, Surgery today, 53(1) (1), 158 - 158, 英語, 国内誌
- (一社)日本Acute Care Surgery学会, 2022年09月, Japanese Journal of Acute Care Surgery, 12(Suppl.) (Suppl.), 149 - 149, 日本語がん化学療法中の急性胆嚢炎症例の検討
- Stapling is the standard method for pancreatic transection during laparoscopic distal pancreatectomy. Although most surgeons use a 60 mm cartridge stapler, space limitations created by laparoscopic surgery make the instrument difficult to handle, especially during pancreatic transection at the neck. Therefore, we currently use a 45 mm cartridge stapler for laparoscopic pancreatic transection at the neck. Between October 2019 and December 2020, we performed pancreatic transection using a 45 mm cartridge stapler in 27 patients. Fifteen patients experienced biochemical leakage, but no patients developed clinically relevant pancreatic fistula. The compactness of the 45 mm cartridge has several benefits: (1) less space is required for flexing, opening, and closing the device; (2) it enables easy insertion of the lower jaw behind the pancreas, even if the dissected space behind the pancreas is narrow; (3) less obstruction of the surgeons' view prevents accidental injury to the surrounding tissues and vessels. These benefits may enable safe pancreatic transection.2022年07月, Surgery today, 53(1) (1), 153 - 157, 英語, 国内誌研究論文（学術雑誌）
- BACKGROUND: Resecting liver tumors located in Couinaud's segment VII is challenging; the efficacy and safety of laparoscopic liver resection for segment VII lesions compared to open liver resection remain unclear. METHODS: Medical records of 84 patients who underwent liver resection of segment VII at Kobe University Hospital and Hyogo Cancer Center between 2010 and 2021 were retrospectively analyzed. Surgical outcomes were compared between laparoscopic liver resection and open liver resection groups using propensity matching analysis. RESULTS: Thirty-one and 53 patients underwent laparoscopic liver resection and open liver resection, respectively. After propensity matching, 29 patients were included in each group. The laparoscopic liver resection group had a significantly longer operation time (407 vs. 305 min, P = 0.002), lower blood loss (100 vs. 230 mL, P = 0.004), and higher postoperative alanine aminotransferase levels (436 vs. 252 IU/L, P = 0.008) than the open liver resection group. In patients with liver cirrhosis, the proportion of patients with postoperative liver-specific complications was higher in the laparoscopic liver resection group than in the open liver resection group (57% vs 11%, P = 0.049), although there was no significant difference in postoperative liver-specific complication rates between the groups in patients without liver cirrhosis. CONCLUSIONS: For liver resection of segment VII, laparoscopic liver resection led to higher postoperative liver damage than open liver resection. Open liver resection may be better for patients with liver cirrhosis to avoid postoperative liver-specific complications. Laparoscopic liver resection could be an acceptable procedure for patients without liver cirrhosis, with some merits such as less blood loss.2022年06月, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 26(11) (11), 2274 - 2281, 英語, 国際誌研究論文（学術雑誌）
- 2022年06月, Annals of surgical oncology, 29(6) (6), 3373 - 3374, 英語, 国際誌
- (一社)日本外科学会, 2022年04月, 日本外科学会定期学術集会抄録集, 122回, SF - 2, 日本語膵頭十二指腸切除術後の早期胆管炎リスク因子の検討
- BACKGROUND: Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy (GPT) for non-metastatic, locally advanced pancreatic cancer (LAPC) remain unclear. This study aimed to determine the factors associated with long-term survival in GPT for non-metastatic LAPC. METHODS: The medical records of 123 patients with LAPC treated with GPT between February 2009 and December 2019 at Hyogo Ion Beam Medical Center were retrospectively reviewed to assess the factors associated with long-term survival outcomes. RESULTS: The median overall survival of the total cohort treated with GPT was 18.7 months. The 1- and 2-year overall, local progression-free, and progression-free survival rates were 70.4% and 35.7%, 78.2% and 59.0%, and 38.6% and 20.8%, respectively. Multivariate analysis revealed that LAPCs at the pancreatic body-tail and those without anterior peripancreatic invasion were independently associated with longer overall survival (P = 0.040 and P = 0.015, respectively). The median overall survival of patients with LAPC at the pancreatic body-tail and those with LAPC without anterior peripancreatic invasion were 24.1 and 28.1 months, respectively. LAPCs at the pancreatic body-tail had a higher volume ratio irradiated over 60 Gy equivalents at gross tumor volume than those at the pancreatic head (P < 0.001). LAPCs with anterior peripancreatic invasion had more peritoneal recurrence within 6 months after GTP than those without anterior peripancreatic invasion (P = 0.039). CONCLUSIONS: GPT is a promising treatment option for patients with LAPC at the pancreatic body-tail and those with LAPC without anterior peripancreatic invasion.2022年02月, Radiation oncology (London, England), 17(1) (1), 32 - 32, 英語, 国際誌研究論文（学術雑誌）
- INTRODUCTION: Although the relationship between systemic inflammatory responses and prognosis has been known in various cancers, it remains unclear which scores are most valuable for determining the prognosis of extrahepatic cholangiocarcinoma. We aimed to verify the usefulness of various inflammation-based scores as prognostic factors in patients with resected extrahepatic cholangiocarcinoma. METHODS: We analyzed consecutive patients undergoing surgical resection for extrahepatic cholangiocarcinoma at our institution between January 2000 and December 2019. The usefulness of the following inflammation-based scores as prognostic factor was investigated: Glasgow prognostic score (GPS), modified Glasgow prognostic score (mGPS), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR), prognostic nutrition index (PNI), C-reactive protein to albumin ratio (CAR), controlling nutritional status (CONUT), and prognostic index (PI). RESULTS: A total of 169 patients were enrolled in this study. Of the nine scores, CAR and CONUT indicated prognostic value. Furthermore, multivariate analysis for overall survival revealed that high CAR (>0.23) was an independent prognostic factor (HR: 1.816, 95%CI: 1.135-2.906, p=0.0129), along with lymph node metastasis and curability. There was no difference in tumor staging and short-term outcomes between the low CAR (≤ 0.23) and high CAR groups. CONCLUSIONS: CAR was the most valuable prognostic score in patients with resected extrahepatic cholangiocarcinoma.2022年01月, Digestive surgery, 39(2-3) (2-3), 65 - 74, 英語, 国際誌研究論文（学術雑誌）
- (一社)日本内視鏡外科学会, 2021年12月, 日本内視鏡外科学会雑誌, 26(7) (7), MO091 - 1, 日本語腹腔鏡下膵頭十二指腸切除導入の経験
- OBJECTIVE: The goal of this retrospective study was to clarify the clinical implications of immunohistochemically detected protein expression for genes that are frequently mutated in pancreatic neuroendocrine tumors (PNETs). BACKGROUND: The clinical management of PNETs is hindered by their heterogenous biological behavior. Whole-exome sequencing recently showed that 5 genes (DAXX/ATRX, MEN1, TSC2, and PTEN) are frequently mutated in PNETs. However, the clinical implications of the associated alterations in protein expression remain unclear. METHODS: We collected Grade 1 and 2 (World Health Organization 2017 Classification) primary PNETs samples from 100 patients who underwent surgical resection. ATRX, DAXX, MEN1, TSC2, and PTEN expression were determined immunohistochemically to clarify their relationships with prognosis and clinicopathological findings. RESULTS: Kaplan-Meier analysis indicated that loss of TSC2 (n = 58) or PTEN (n = 37) was associated with significantly shorter overall survival, and that loss of TSC2 or ATRX (n = 41) was associated with significantly shorter recurrence-free survival. Additionally, loss of ATRX or TSC2 was significantly associated with nodal metastasis. In a multivariate analysis, combined loss of TSC2 and ATRX (n = 31) was an independent prognostic factor for shorter recurrence-free survival (hazard ratio 10.1, 95% confidence interval 2.1-66.9, P = 0.003) in G2 PNETs. CONCLUSIONS: Loss of ATRX, TSC2, and PTEN expression might be useful as a method of clarifying the behavior and clinical outcomes of Grade 1 and 2 PNETs in routine clinical practice. Combined loss of TSC2 and ATRX had an especially strong, independent association with shorter recurrence-free survival in patients with G2 PNETs. Loss of pairs in ATRX, TSC2, or PTEN would be useful for selecting the candidate for postoperative adjuvant therapy.2021年12月, Annals of surgery, 274(6) (6), e949-e956, 英語, 国際誌研究論文（学術雑誌）
- A 68-year-old man who had undergone distal gastrectomy for gastric cancer 3 years previously, presented to our hospital for examination of dilatation of the main pancreatic duct on follow-up computed tomography and magnetic resonance cholangiopancreatography. After examination, he was diagnosed with early-stage pancreatic cancer and distal pancreatectomy (DP) was planned. With informed consent, we performed indocyanine green (ICG) fluorography during DP and digital subtraction angiography (DSA) of vessels supplying the remnant stomach immediately before and after DP. On ICG fluorography, the remnant stomach gradually became fluoresced starting at the area of the lesser curvature, and the fluorescence eventually intensified over the entire area of the remnant stomach to the same brightness as that of the liver and duodenum. On DSA following DP, the terminal branches of the left inferior phrenic artery (LIPA) were distributed to more than half of the area of the remnant stomach, centering around the proximal area. It is useful to confirm blood flows to the remnant stomach by ICG fluorography using a near-infrared imaging camera during DP. We found that the LIPA played an important role in maintaining the blood supply to the remnant stomach in the absence of the left gastric artery and splenic artery.2021年12月, Clinical journal of gastroenterology, 14(6) (6), 1749 - 1755, 英語, 国内誌研究論文（学術雑誌）
- BACKGROUND: Although liver transplantation is widely accepted as the therapeutic strategy for end-stage liver failure, complication of hepatic venous outflow obstruction remains lethal. Currently, ensuring a single wide orifice in both the graft and recipient inferior vena cava has been proposed to avoid hepatic venous outflow obstruction with no theoretical concept. METHODS: We herein report a standardization technique for the reconstruction of the hepatic vein based on the causal analysis. RESULTS: During the put-in process, the graft must be positioned in contact with the recipient diaphragm and slightly pushed to the cranial direction to simulate the state after abdominal closure. Because there is no extra space between the graft and diaphragm, the graft could not rotate about the anastomotic site of the inferior vena cava toward the diaphragm after abdominal closure as the intestinal pressure increases, and accordingly hepatic venous outflow obstruction does not develop. CONCLUSIONS: With this concept, all transplant surgeons can successfully and easily perform hepatic vein reconstruction without total clamping of the inferior vena cava and without outflow block.2021年12月, Transplantation proceedings, 53(10) (10), 2934 - 2938, 英語, 国際誌研究論文（学術雑誌）
- In this single-center, retrospective cohort study, we aimed to elucidate simple metabolic markers or surrogate indices of β-cell function that best predict long-term insulin independence and goal glycemic HbA1c control (HbA1c ≤ 6.5%) after total pancreatectomy with islet autotransplantation (TP-IAT). Patients who underwent TP-IAT (n = 371) were reviewed for metabolic measures before TP-IAT and for insulin independence and glycemic control at 1, 3, and 5 years after TP-IAT. Insulin independence and goal glycemic control were achieved in 33% and 68% at 1 year, respectively. Although the groups who were insulin independent and dependent overlap substantially on baseline measures, an individual who has abnormal glycemia (prediabetes HbA1c or fasting glucose) or estimated IEQs/kg < 2500 has a very high likelihood of remaining insulin dependent after surgery. In multivariate logistic regression modelling, metabolic measures correctly predicted insulin independence in about 70% of patients at 1, 3, and 5 years after TP-IAT. In conclusion, metabolic testing measures before surgery are highly associated with diabetes outcomes after TP-IAT at a population level and correctly predict outcomes in approximately two out of three patients. These findings may aid in prognostic counseling for chronic pancreatitis patients who are likely to eventually need TP-IAT.2021年10月, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 21(10) (10), 3411 - 3420, 英語, 国際誌研究論文（学術雑誌）
- Understanding the anti-carbohydrate antibody response toward epitopes expressed on porcine cells, tissues, and organs is critical to advancing xenotransplantation toward clinical application. In this study, we determined IgM and IgG antibody specificities and relative concentrations in five cynomolgus monkeys at baseline and at intervals following intraportal xenotransplantation of adult porcine islets. This study utilized a carbohydrate antigen microarray that comprised more than 400 glycoconjugates, including historically reported α-Gal and non-α-Gal carbohydrate antigens with various modifications. The elicited anti-carbohydrate antibody responses were predominantly IgM compared to IgG in 4 out of 5 monkeys. Patterns of elicited antibody responses greater than 1.5 difference (log2 base units; 2.8-fold on a linear scale) from pre-serum to post-serum sampling specific for carbohydrate antigens were heterogeneous and recipient-specific. Increases in the elicited antibody response to α-Gal, Sda, GM2 antigens, or Lexis X antigen were found in individual monkeys. The novel carbohydrate structures Galβ1-4GlcNAcβ1-3Galβ1 and N-linked glycans with Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure were common targets of elicited IgM antibodies. These results provide important insights into the carbohydrate epitopes that elicit antibodies following pig-to-monkey islet xenotransplantation and reveal possible targets for gene editing.2021年, PloS one, 16(6) (6), e0253029, 英語, 国際誌研究論文（学術雑誌）
- 2020年11月, Xenotransplantation, 27(6) (6), e12653, 英語, 国際誌研究論文（学術雑誌）
- Islet yield is an important predictor of acceptable glucose control after total pancreatectomy with islet autotransplantation (TP-IAT). We assessed if pancreas volume calculated with preoperative MRI could assess islet yield and postoperative outcomes. We reviewed dynamic MRI studies from 154 adult TP-IAT patients (2009-2016), and associations between calculated volumes and digest islet equivalents (IEQs) were tested. In multivariate regression analysis, pancreas volume (P < .001) and preoperative HbA1c levels (P = .009) were independently associated with digest IEQs. The IEQ prediction formula was calculated according to each preoperative HbA1c level, (a) pancreas volume × 5800 for HbA1c ≥ 6.5, (b) pancreas volume × 10 000 for HbA1c ≥5.7/<6.5 and (iii) pancreas volume × 11 400 for HbA1c < 5.7. The formula was internally validated with 28 TP-IAT patients between 2017 and 2018 (r2 = .657 and r2 = .710 when restricted to 24 patients without prior pancreatectomy). An estimated IEQs/Body Weight (kg) ≥3700 predicted HbA1c ≤6.5 and insulin independence at 1 year after TP-IAT with 77% and 88% sensitivity and 55% and 43% specificity, respectively. The combination of pancreas volume and preoperative HbA1c levels may be useful to estimate islet yield. Estimated IEQs were reasonably sensitive to predict acceptable glucose control at 1 year.2020年08月, Clinical transplantation, 34(8) (8), e14008, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: Engineering of α-Galactosyltransferase gene-knockout pigs circumvented hyperacute rejection of pig organs after xenotransplantation in non-human primates. Overcoming this hurdle revealed the importance of non-α-Gal carbohydrate antigens in the immunobiology of acute humoral xenograft rejection. METHODS: This study analyzed serum from seven naïve cynomolgus monkeys (blood type O/B/AB = 3/2/2) for the intensity of natural IgM and IgG signals using carbohydrate antigen microarray, which included historically reported α-Gal and non-α-Gal carbohydrate antigens with various modifications. RESULTS: The median (range) of IgM and IgG signals were 12.71 (7.23-16.38) and 9.05 (7.23-15.90), respectively. The highest IgM and IgG signals with narrowest distribution were from mono- and disaccharides, followed by modified structures. Natural anti-α-Gal antibody signals were medium to high in IgM (11.2-15.9) and medium in IgG (8.5-11.6) spectra, and was highest with Lac core structure (Galα1-3Galβ1-4Glc, iGb3) and lowest with LacNAc core structure (Galα1-3Galβ1-4GlcNAc). Similar signal intensities (up to 15.8 in IgM and up to 11.8 in IgG) were observed for historically detected natural non-α-Gal antigens, which included Tn antigen, T antigen, GM2 glycolipid, and Sda antigen. The hierarchical clustering analysis revealed the presence of clusters of anti-A antibodies and was capable of distinguishing between the blood group B and AB non-human primates. CONCLUSIONS: The results presented here provide the most comprehensive evaluation of natural antibodies present in cynomolgus monkeys.2020年03月, Xenotransplantation, 27(2) (2), e12567, 英語, 国際誌研究論文（学術雑誌）
- OBJECTIVES: Islet transplantation is an emerging treatment option for type 1 diabetes but its application is limited by the shortage of human pancreas donors. Characterization of the N- and O-glycan surface antigens that vary between human and genetically engineered porcine islet donors could shed light on targets of antibody mediated rejection. METHODS: N- and O-glycans were isolated from human and adult porcine islets and analyzed using matrix-assisted laser-desorption time-of-flight mass spectrometry (MALDI-TOF-MS) and electrospray ionization mass spectrometry (ESI-MS/MS). RESULTS: A total of 57 porcine and 34 human N-glycans and 21 porcine and 14 human O-glycans were detected from cultured islets. Twenty-eight of which were detected only from porcine islets, which include novel xenoantigens such as high-mannose type N-glycans with core fucosylation and complex-type N-glycans with terminal neuraminic acid residues. Porcine islets have terminal N-glycolylneuraminic acid (NeuGc) residue in bi-antennary N-glycans and sialyl-Tn O-glycans. No galactose-α-1,3-galactose (α-Gal) or Sda epitope were detected on any of the islets. CONCLUSIONS: These results provide important insights into the potential antigenic differences of N- and O-glycan profiles between human and porcine islets. Glycan differences may identify novel gene targets for genetic engineering to generate superior porcine islet donors.2020年, PloS one, 15(11) (11), e0241249, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: Lactate production is exacerbated by surgical stress. We sought to determine whether branched-chain amino acid (BCAA) supplementation could decrease blood lactate levels in patients undergoing hepatectomy. METHODS: A total of 275 consecutive patients who underwent hepatectomy of ≥2 segments were retrospectively reviewed. Blood lactate levels in patients treated with BCAA supplementation before hepatectomy (December 2011 to December 2016) were compared with levels in patients who were not pretreated (January 2008 to November 2011). RESULTS: Postoperative lactate levels were significantly lower in patients who received preoperative BCAA supplementation than in those who did not (2.6 vs 3.4 mmol/L; P < .001). Intraoperative blood lactate levels, which were evaluated after induction of general anesthesia, were also lower in those who received BCAA supplementation than in those who did not (1.1 vs 1.5 mmol/L, respectively; P < .001). A multiple regression analysis revealed that preoperative BCAA supplementation was independently associated with decreased postoperative and intraoperative lactate levels (P = .030 and P < .001, respectively). CONCLUSION: Preoperative BCAA supplementation decreased intraoperative and postoperative blood lactate levels in patients undergoing major hepatectomy.2019年02月, JPEN. Journal of parenteral and enteral nutrition, 43(2) (2), 220 - 225, 英語, 国際誌研究論文（学術雑誌）
- (株)アークメディア, 2019年01月, 肝胆膵, 78(1) (1), 79 - 86, 日本語
- 2018年12月, Annals of surgical oncology, 25(Suppl 3) (Suppl 3), 800 - 801, 英語, 国際誌研究論文（学術雑誌）
- PURPOSE: This study was designed to assess the potential role of the preoperative serum level of elastase 1 as a risk factor for recurrence in patients with resectable well-differentiated pancreatic neuroendocrine neoplasms (PanNETs). METHODS: Preoperative serum elastase 1 levels were measured in 53 patients with PanNETs who underwent complete tumor resection in two tertiary referral centers between January 2004 and June 2017. The preoperative elastase 1 levels were correlated with clinicopathological characteristics, including tumor recurrence and recurrence-free survival. RESULTS: The median elastase 1 level was 96 ng/dL (range: 21-990 ng/dL). Preoperative serum elastase 1 levels were significantly higher in those with tumors ≥ 20 mm in diameter (vs. < 20 mm, P = 0.018), WHO grade 2 (vs. grade 1, P = 0.035), and microscopic venous invasion (vs. without venous invasion, P = 0.039). The median preoperative serum level of elastase 1 was higher in patients with recurrence than in those without recurrence (251 vs. 80 ng/dL, P = 0.004). Receiver operating characteristic analysis of elastase 1 levels showed that a cutoff level of 250 ng/dL was associated with postoperative recurrence, with 63% sensitivity, 100% specificity, and 94% overall accuracy. Patients with higher elastase 1 levels showed significantly worse recurrence-free survival than that of those with lower levels (2-year recurrence-free survival rate: 25% and 92%, respectively, P < 0.001). CONCLUSIONS: Our data provide the first evidence that high preoperative elastase 1 levels may be a risk factor for postoperative recurrence in patients with resectable PanNETs.2018年10月, Annals of surgical oncology, 25(11) (11), 3358 - 3364, 英語, 国際誌研究論文（学術雑誌）
- 固形臓器移植後の急性移植片対宿主病(GVHD)は、造血幹細胞移植後に比べ頻度が低く、病態や危険因子について未だ不明な点が多い。膵臓移植後GVHDの報告例について著者らの経験を踏まえて考察し、特にHLA一方向性0ミスマッチと言われる特殊な危険因子との関係について報告した。HLA型一方向性0ミスマッチ症例は、必ずしも全例がGVHDを起こすわけではないが、一度発症すると予後不良であることが示唆された。(一社)日本移植学会, 2018年05月, 移植, 53(1) (1), 71 - 77, 日本語
- BACKGROUND: The prognostic impact of pancreatic ductal adenocarcinoma (PDAC) invasion to the splenic vessel is controversial. OBJECTIVE: The aim of this study was to assess the clinical value of pathological and radiological splenic vessel invasion in PDACs of the body and tail. METHODS: Medical records of patients with resectable PDAC of the body and tail who underwent distal pancreatectomy between 2003 and 2016 at the Kobe University Hospital were retrospectively analyzed. RESULTS: Overall, 68 patients (29 female and 39 male patients) were enrolled. Pathologically determined splenic vein invasion (p-SV) and splenic artery invasion (p-SA) were identified in 21 (30.9%) and 5 (7.4%) patients, respectively. The p-SV (but not p-SA) was an independent prognostic factor in multivariate analysis (p = 0.009). On analysis of recurrence patterns, patients with PDAC positive for p-SV were at a higher risk for liver metastasis (p = 0.022); however, the associations were not significant for other recurrence patterns. Liver metastasis occurred earlier in patients who were positive for p-SV (p = 0.015). Preoperative computed tomography effectively diagnosed pathological vessel invasion (SV: sensitivity, 95.2%, specificity, 72.3%; SA: sensitivity, 100%, specificity, 84.1%). Radiological SV invasion remained significant in multivariate analysis regarding postoperative survival (p = 0.007), and was also associated with early liver metastases (p = 0.008). CONCLUSIONS: Pathological/radiological SV invasion were independent adverse prognostic factors associated with early liver metastasis in patients with PDAC of the body/tail. Assessment of these findings may be useful in determining optimal therapeutic options in these patients.2018年03月, Annals of surgical oncology, 25(3) (3), 638 - 646, 英語, 国際誌研究論文（学術雑誌）
- 2017年11月, PANCREATOLOGY, 17(6) (6), 956 - 961, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- (株)癌と化学療法社, 2017年11月, 癌と化学療法, 44(12) (12), 1886 - 1888, 日本語
- (株)癌と化学療法社, 2017年11月, 癌と化学療法, 44(12) (12), 1976 - 1978, 日本語
- BACKGROUND: Elevations in blood lactate levels have been associated with poor postoperative outcome. The aim of the present study was to determine if preoperative supplementation with branched-chain amino acids (BCAA) decreases postoperative blood lactate levels in patients undergoing pancreatoduodenectomy. METHODS: The cases of 223 consecutive patients who underwent pancreatoduodenectomy were retrospectively reviewed. Postoperative blood lactate levels in patients who were treated with BCAA supplementation before pancreatoduodenectomy (December 2011-December 2014) were compared with levels in patients who were not pretreated (January 2008-November 2011). RESULTS: Postoperative lactate levels were significantly lower in patients who received preoperative BCAA supplementation than in patients who did not (2.6 vs 3.1 mmol/L, P = .005), although preoperative blood lactate levels were statistically equivalent between the groups. In the univariate analysis, preoperative BCAA supplementation, preoperative lactate levels, operation time, and postoperative glucose levels were associated with postoperative lactate levels. A multiple regression analysis was performed among the 4 factors, and the preoperative use of BCAA supplementation was independently correlated with postoperative lactate levels ( P = .046). CONCLUSIONS: Preoperative BCAA supplementation decreased postoperative blood lactate levels. These results suggest that preoperative BCAA supplementation may help patients recover after surgery.2017年06月, JPEN. Journal of parenteral and enteral nutrition, 148607117718494 - 148607117718494, 英語, 国際誌研究論文（学術雑誌）
- We report a case of an internal hernia through a transverse mesocolon defect after laparoscopic distal pancreatectomy. The patient was a 58-year-old man with an intraductal papillary mucinous neoplasm of the pancreatic body who underwent laparoscopic distal pancreatectomy. During surgery, an approximately 5-cm defect in the transverse mesocolon was inadvertently made. The defect was not closed as it was thought to be large enough to preclude incarceration. However, the patient developed a bowel obstruction 2 months postoperatively. Laparotomy revealed that a loop of the proximal jejunum herniated through the defect and was adherent to the stapled pancreatic stump. An additional loop of the jejunum was herniated through the narrowed mesenteric defect. To our knowledge, this is the first case of an internal hernia through a transverse mesocolon defect after laparoscopic distal pancreatectomy.2017年05月, Asian journal of endoscopic surgery, 10(2) (2), 187 - 190, 英語, 国内誌研究論文（学術雑誌）
- BACKGROUND: The biological behavior of well-differentiated neuroendocrine tumors of the pancreas (PNETs) is difficult to predict. This study was designed to determine whether involvement of the main pancreatic duct (MPD) serves as a poor prognostic factor for PNETs. METHODS: The involvement of the MPD in PNETs was defined as ductal stenosis inside the tumor mass associated with distal MPDs more than twofold larger in diameter than the proximal ducts. We examined the correlation between MPD involvement and other clinicopathological parameters, including nodal metastasis and recurrence-free survival, in 101 patients treated consecutively at three referral centers in Japan. All patients underwent surgical resection. RESULTS: MPD involvement was observed in 13 of the 101 cases (13%) and was associated with multiple unfavorable clinicopathological features (e.g., larger tumor size, higher histological grade, more frequent nodal metastasis, and higher recurrence rates). Patients with MPD involvement also showed significantly worse recurrence-free survival than did those without ductal involvement (P < 0.001), with a 5 years recurrence-free rate of 41%. On multivariate analysis, MPD involvement was significantly associated with nodal metastasis [odds ratio (OR) 16; 95% confidence interval (CI) 3.8-89; P < 0.001] and recurrence (OR 8.0; 95% CI 1.7-46; P = 0.009). The radiology-pathology correlation revealed that stenosis of the MPD was due to periductal and/or intraductal tumor invasion. Cases with MPD involvement had microscopic venous invasion (P = 0.010) and perineural infiltration (P = 0.002) more frequently than did those with no ductal infiltration. CONCLUSIONS: MPD involvement in PNETs may serve as an imaging sign indicating an aggressive clinical course.2017年04月, Annals of surgical oncology, 24(4) (4), 1127 - 1133, 英語, 国際誌研究論文（学術雑誌）
- 2017年03月, PANCREATOLOGY, 17(2) (2), 291 - 294, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- The present study aimed to elucidate whether the stemness molecule, CD133, is expressed in well-differentiated pancreatic neuroendocrine tumors (PanNETs; World Health Organization grades 1 and 2) and establish its clinical relevance using 2 separate cohorts. In the first series (n = 178) in which tissue microarrays were available, immunohistochemistry revealed that CD133 was expressed in 14 cases (8%). CD133+ PanNETs had higher TNM stages (P < .01), more frequent lymphovascular invasion (P = .01), and higher recurrence rates (P = .01). In the second cohort (n = 56), the expression of CD133 and CK19 was examined in whole tissue sections. CD133 and CK19 were positive in 10 (18%) and 36 (64%) cases, respectively. CD133 expression correlated with higher pT scores (P < .01), the presence of microscopic venous infiltration (P = .03), and shorter disease-free periods (P < .01). When cases were divided into grade 1 and 2 neoplasms, patients with CD133+ PanNET continued to have shorter disease-free periods than did those with CD133- tumors in both groups (P < .01 and P = .02, respectively). Although CK19+ cases had shorter disease-free periods than did CK19- cases in the whole cohort (P = .02), this difference was less apparent in subanalyses of grade 1 and 2 cases. CD133 expression also appeared to be an independent predictive factor for tumor recurrence in a multivariate analysis (P = .018). The CD133 phenotype was identical between primary and metastatic foci in 17 of 18 cases from which tissues of metastatic deposits were available. In conclusion, the combination of CD133 phenotyping and World Health Organization grading may assist in stratifying patients in terms of the risk of progressive clinical courses.2017年03月, Human pathology, 61, 148 - 157, 英語, 国際誌研究論文（学術雑誌）
- (株)癌と化学療法社, 2016年11月, 癌と化学療法, 43(12) (12), 1988 - 1990, 日本語
- (株)癌と化学療法社, 2016年11月, 癌と化学療法, 43(12) (12), 2193 - 2195, 日本語
- 2016年09月, PANCREATOLOGY, 16(5) (5), 882 - 887, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- OBJECTIVES: The aim of this study was to determine the incidence rate and clinical features of second primary pancreatic ductal carcinoma (SPPDC) in the remnant pancreas after pancreatectomy for pancreatic ductal carcinoma (PDC). METHODS: Data of patients undergoing R0 resection for PDC at a single high-volume center were reviewed. SPPDC was defined as a tumor in the remnant pancreas after R0 resection for PDC, and SPPDC met at least one of the following conditions: 1) the time interval between initial pancreatectomy and development of a new tumor was 3 years or more; 2) the new tumor was not located in contact with the pancreatic stump. We investigated the clinical features and treatment outcomes of patients with SPPDC. RESULTS: This study included 130 patients who underwent surgical resection for PDC between 2005 and 2014. Six (4.6%) patients developed SPPDC. The cumulative 3- and 5-year incidence rates were 3.1% and 17.7%, respectively. Four patients underwent remnant pancreatectomy for SPPDC. They were diagnosed with the disease in stage IIA or higher and developed recurrence within 6 months after remnant pancreatectomy. One patient received carbon ion radiotherapy and survived 45 months. One patient refused treatment and died 19 months after the diagnosis of SPPDC. CONCLUSIONS: The incidence rate of SPPDC is not negligible, and the cumulative 5-year incidence rate of SPPDC is markedly high. Post-operative surveillance of the remnant pancreas is critical for the early detection of SPPDC, even in long-term survivors after PDC resection.2016年07月, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 16(4) (4), 615 - 620, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- 医学図書出版(株), 2016年05月, 胆と膵, 37(5) (5), 455 - 460, 日本語
- We herein report a rare case of a patient who developed a spindle cell tumor at the inferior mesenteric artery clipping site. A 58-year-old man underwent laparoscopy-assisted sigmoid colectomy for sigmoid colon cancer. As follow-up, CT scans were performed every 6 months after the primary surgery. At the 1-year CT, an nodular soft tissue density mass measuring 54 mm in diameter was found in the mesentery. Although we initially suspected locoregional recurrence of the colon cancer resected 1 year earlier, PET-CT showed that the tumor was unrelated to the previous cancer. During the subsequent laparotomy, the mass appeared to originate from the inferior mesenteric artery clipping site, and it adhered to the jejunum and the left ureter. We completely resected the tumor and part of the jejunum, which we separated from the abdominal aorta and left ureter. The tumor was histologically diagnosed of a spindle cell tumor. The patient has been free from recurrence since the surgery more than 4.5 years ago. Preoperative PET-CT was helpful in ruling out local recurrence of colon cancer, which might have made palliative care a better option than surgical resection.2016年02月, Asian journal of endoscopic surgery, 9(1) (1), 68 - 71, 英語, 国内誌研究論文（学術雑誌）
- (株)癌と化学療法社, 2014年11月, 癌と化学療法, 41(12) (12), 2178 - 2180, 日本語
- 膵癌術後左側門脈圧亢進症に対しHassab手術が有効であった1例Here, we report a case of Hassab's operation for left-sided portal hypertension after pancreatoduodenectomy. A 69-year old man underwent pancreatoduodenectomy for pancreatic cancer in 2006 in which the splenic vein was ligated near the portal vein and then divided. The patient suffered repeated episodes of anemia between 2010 and 2013. However, we could not identify the bleeding site at that time. In 2011, local recurrence was detected. Disease progression occurred despite chemotherapy treatment, which was then discontinued. The left-sided portal hypertension gradually progressed, and the collateral vessels became dilated. In 2014, he was examined in our department for gastrointestinal bleeding. An upper gastrointestinal endoscopy revealed bleeding from gastric varices. Gastrointestinal bleeding ceased after endoscopic injection sclerotherapy ( EIS) was performed; however, the bleeding recurred. Balloon retrograde transvenous occlusion (BRTO) could not be performed because blood flow was not detected within the gastro-renal shunt. An emergency surgery was performed. Surgical splenectomy and devascularization (Hassab's operation) were performed. After surgery, the gastric body varices and gastrointestinal anastomosis disappeared and the bleeding did not occur. He is currently receiving outpatient treatment.(株)癌と化学療法社, 2014年11月, 癌と化学療法, 41(12) (12), 2214 - 6, 日本語, 国内誌研究論文（学術雑誌）
- (株)癌と化学療法社, 2012年09月, 癌と化学療法, 39(9) (9), 1399 - 1402, 日本語
- 1987年11月から2008年12月までに施行した原発性乳癌切除719例のうち、80歳以上の超高齢者45名46側(6.4%)の臨床病理学的特徴と治療成績を検討した。全例しこりを主訴として来院したが、皮膚浸潤を伴うものが多く、病悩期間が長い傾向にあり、91%が何らかの合併症を有していた。病期はIIIb期の比率が高く、60%の症例に縮小手術が選択されており、全症例の5年生存率は56.6%と比較的良好であった。また、単変量解析で予後に影響を及ぼしたと思われる因子は、認知症の有無・PS・内分泌感受性・腫瘍径・内分泌療法施行の有無であり、年齢・手術の根治度・術前遠隔転移検索実施の有無・病悩期間・病期・HER2発現の有無・核グレードに有意差は認めなかった。以上より、従来の治療方針を今後も継続していく方向性を確認できた。(株)篠原出版新社, 2012年08月, 乳癌の臨床, 27(4) (4), 433 - 438, 日本語
- 日本消化器病学会近畿支部第124回例会, 2026年01月, 日本語, 国内会議切除不能進行肝細胞癌に対するアテゾリズマブ・ベバシズマブ併用療法後コンバージョン治療の意義シンポジウム・ワークショップパネル（公募）
- 第27回手稲渓仁会病院 NST セミナー, 2026年01月, 日本語, 国内会議外科医が斬り込む！術後回復と栄養管理の落とし穴口頭発表（招待・特別）
- 第3階膵・消化管神経内分泌腫瘍 Meet The Expert in Kobe, 2025年12月, 日本語, 国内会議神戸大学肝胆膵外科の未来への挑戦口頭発表（招待・特別）
- 第38回日本内視鏡外科学会総会, 2025年12月, 日本語, 国内会議腹腔鏡下再肝切除に対する IWATE criteria の検証口頭発表（一般）
- 第38回日本内視鏡外科学会総会, 2025年12月, 日本語, 国内会議鑑別困難な組織球肉腫の診断に腹腔鏡下脾臓摘出術が有用であった一例口頭発表（一般）
- 第38回日本内視鏡外科学会総会, 2025年12月, 日本語, 国内会議肝複数個切除における腹腔鏡アプローチの有効性についての検討口頭発表（一般）
- 第38回日本内視鏡外科学会総会, 2025年12月, 日本語, 国内会議腹腔鏡下肝亜区域切除術における ICG 蛍光法による領域同定の有用性口頭発表（一般）
- 第38回日本内視鏡外科学会総会, 2025年12月, 日本語, 国内会議重複胆嚢を伴う膵・胆管合流異常に対しロボット支援総胆管拡張症手術を施行した 1 例口頭発表（一般）
- 第38回日本内視鏡外科学会総会, 2025年12月, 日本語, 国内会議膵頭十二指腸切除後症例に対する腹腔鏡下肝切除における Pringle 法確保手技の定型化口頭発表（一般）
- 第38回日本内視鏡外科学会総会, 2025年12月, 日本語, 国内会議開腹、腹腔鏡下膵体尾部切除術後のドレーンアミラーゼ値の比較検討口頭発表（一般）
- 第38回日本内視鏡外科学会総会, 2025年12月, 日本語, 国内会議ロボット支援手術導入期におけるロボット支援と腹腔鏡下脾温存尾側膵切除の術後成績の比較口頭発表（一般）
- 第38回日本内視鏡外科学会総会, 2025年12月, 日本語, 国内会議低侵襲肝切除を進化させる可視化技術：超音波・シミュレーション・蛍光・AI・スペクトル画像の統合的展開シンポジウム・ワークショップパネル（公募）
- 第46回日本肝臓学会西部会, 2025年12月, 日本語, 国内会議遠隔転移を伴う高度進行肝細胞癌に対して集学的治療により Drug-free Cancer-free を達成した1例口頭発表（招待・特別）
- 第19回肝臓内視鏡外科研究会, 2025年11月, 日本語, 国内会議ロボット支援肝切除におけるCUSA併用hybridアプローチ公開講演，セミナー，チュートリアル，講習，講義等
- 第37回下野栄養管理研究会, 2025年11月, 日本語, 国内会議膵疾患から見る低亜鉛血症の最前線口頭発表（招待・特別）
- 第23回日本消化器外科学会大会（JDDW2025）, 2025年10月, 日本語, 国内会議解剖学的切除可能膵癌の予後に対するサルコペニアの影響ポスター発表
- 第23回日本消化器外科学会大会（JDDW2025）, 2025年10月, 日本語, 国内会議再肝切除における肝門部操作の影響と腹腔鏡手術の安全性ポスター発表
- 第23回日本消化器外科学会大会（JDDW2025）, 2025年10月, 日本語, 国内会議転移部位別奏効率から考える肝細胞癌薬物療法の治療選択ポスター発表
- 第23回日本消化器外科学会大会（JDDW2025）, 2025年10月, 日本語, 国内会議特殊型膵癌切除後の治療成績についてポスター発表
- 第23回日本消化器外科学会大会（JDDW2025）, 2025年10月, 日本語, 国内会議巨大肝腫瘍に対するAnterior approachを用いた腹腔鏡下肝後区域切除ポスター発表
- 第19回膵癌術前治療研究会, 2025年10月, 日本語, 国内会議当科における局所進行切除不能膵癌に対する Conversion Surgery の成績と課題口頭発表（一般）
- 第19回膵癌術前治療研究会, 2025年10月, 日本語, 国内会議膵癌術前化学療法後切除例における術後補助化学療法の有用性に関する検討口頭発表（一般）
- 第19回膵癌術前治療研究会, 2025年10月, 日本語, 国内会議術前治療後に切除したBorderline resectable 膵癌症例における早期再発危険因子の解析シンポジウム・ワークショップパネル（公募）
- 第19回膵癌術前治療研究会, 2025年10月, 日本語, 国内会議BR膵癌に対する至適術前治療期間の検討シンポジウム・ワークショップパネル（公募）
- 第19回膵癌術前治療研究会, 2025年10月, 日本語, 国内会議座長（一般演題5（ポスター））その他
- 第61回日本移植学会総会, 2025年10月, 日本語, 国内会議膵腎同時移植後3ヶ月で発症した外腸骨動脈吻合部仮性動脈瘤に対し血管内治療を施行し移植膵グラフトを温存し得た一例ポスター発表
- 第61回日本移植学会総会, 2025年10月, 日本語, 国内会議術前ICU入室症例に対する生体肝移植の術後成績の検討ポスター発表
- 第61回日本移植学会総会, 2025年10月, 日本語, 国内会議当院におけるICU管理後の肝移植の治療成績ポスター発表
- 第61回日本移植学会総会, 2025年10月, 日本語, 国内会議一過性門脈ガスを生じた高齢ドナーからの脳死肝移植の一例ポスター発表
- 第52回日本膵切研究会, 2025年08月, 日本語, 国内会議IgG4関連血管炎により脾動脈の処理に難渋した腹腔鏡下脾温存膵体尾部切除術の1例ポスター発表
- 第52回日本膵切研究会, 2025年08月, 日本語, 国内会議膵癌に対する肝動脈門脈合併膵切除直後に小腸間膜の捻れによる門脈血流不全に対して再手術を行った1例口頭発表（一般）
- 第56回日本膵臓学会大会, 2025年07月, 日本語, 国内会議切除可能膵癌の予後に対する GLIM 基準の影響シンポジウム・ワークショップパネル（公募）
- 第56回日本膵臓学会大会, 2025年07月, 日本語, 国内会議80 歳以上の Resectable，Borderline resectable 膵癌患者の治療成績についてシンポジウム・ワークショップパネル（公募）
- 第56回日本膵臓学会大会, 2025年07月, 日本語, 国内会議2cm 以下の小膵神経内分泌腫瘍に対する EUS 下生検の有用性シンポジウム・ワークショップパネル（公募）
- 第80回日本消化器外科学会, 2025年07月, 日本語, 国内会議当科における吸収性スペーサー留置術 75 例の検討口頭発表（一般）
- 第80回日本消化器外科学会, 2025年07月, 日本語, 国内会議主膵管拡張を伴う非浸潤・微小浸潤 IPMN 術後残膵再発に対する予定残膵主膵管拡張の影響口頭発表（一般）
- 第80回日本消化器外科学会, 2025年07月, 日本語, 国内会議高齢者に対する膵全摘，残膵全摘の短期・長期成績について口頭発表（一般）
- 第80回日本消化器外科学会, 2025年07月, 日本語, 国内会議膵頭十二指腸切除術後の新規発症脂肪肝患者における lipoprotein 解析口頭発表（一般）
- 第80回日本消化器外科学会, 2025年07月, 日本語, 国内会議ロボット支援膵切除における新機種導入の経験口頭発表（一般）
- 第80回日本消化器外科学会, 2025年07月, 日本語, 国内会議複数機種ロボット支援手術の運用と教育:肝胆膵外科における da Vinci と hinotori の導入事例口頭発表（一般）
- The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), 2025年07月, 英語, 国内会議A Case of Successful Conversion Hepatectomy Following Durvalumab plus Tremelimumab Therapy under Nasogastric Feeding for Advanced Vp4 Hepatocellular Carcinomaポスター発表
- The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), 2025年07月, 英語, 国内会議Impact of tumor size on liver regeneration after hepatectomyポスター発表
- The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), 2025年07月, 英語, 国内会議Impact of Initial Hepatectomy With Hilar Manipulation on Short-Term Outcomes of Repeat Hepatectomy for Recurrent Liver Cancerポスター発表
- The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), 2025年07月, 英語, 国内会議Laparoscopic right posterior sectionectomy using the anterior approach for huge hepatocellular carcinomaポスター発表
- The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), 2025年07月, 英語, 国内会議Impact of Post-Hepatectomy Liver Failure on Long-Term Liver Function and Prognosis in Patients with Hepatocellular Carcinomaポスター発表
- 第61回日本肝癌研究会, 2025年07月, 日本語, 国内会議肝門部操作を伴う肝切除後の再肝切除に関する検討口頭発表（一般）
- 第61回日本肝癌研究会, 2025年07月, 日本語, 国内会議当院における低侵襲肝切除の実際―ICG 蛍光法と複数機種ロボット支援の最適活用―シンポジウム・ワークショップパネル（公募）
- 日本外科代謝栄養学会第62回学術集会, 2025年07月, 日本語, 国内会議膵疾患から見る低亜鉛血症の最前線公開講演，セミナー，チュートリアル，講習，講義等
- The 12th Summer Seminar in Okinawa 2025, 2025年06月, 日本語, 国内会議ロボ肝が進む時代にこそ光るラパ肝口頭発表（一般）
- 第32回日本肝がん分子標的治療研究会, 2025年06月, 日本語, 国内会議切除不能肝細胞癌に対するアテゾリズマブ・ベバシズマブ併用療法リチャレンジの治療成績ポスター発表
- 第32回日本肝がん分子標的治療研究会, 2025年06月, 日本語, 国内会議Vp4 巨大肝細胞癌に対して経鼻経管栄養下に Durvalumab ＋ Tremelimumab 併用療法を施行し conversion 肝切除を達成した 1 例ポスター発表
- 第32回日本肝がん分子標的治療研究会, 2025年06月, 日本語, 国内会議肝区域切除および葉切除後再発に対する免疫チェックポイント阻害剤の治療成績と安全性の検討ポスター発表
- 第32回日本肝がん分子標的治療研究会, 2025年06月, 日本語, 国内会議肝細胞癌腫瘍学的切除可能性分類に基づいた肝切除および薬物療法治療成績の検証ポスター発表
- 第37回日本肝胆膵外科学会学術集会, 2025年06月, 英語, 国内会議Aretrospective study on the accuracy of preoperative diagnosis of pancreatic carcinoma in situポスター発表
- 第37回日本肝胆膵外科学会学術集会, 2025年06月, 英語, 国内会議Technical tips and postoperative management for prevention of postoperative pancreatic fistula after minimally invasive distal pancreatectomyポスター発表
- 第37回日本肝胆膵外科学会学術集会, 2025年06月, 英語, 国内会議Identifying the Best Nutritional Prognostic Marker for Survival in Pancreatic Ductal Adenocarcinoma Patientsポスター発表
- 第37回日本肝胆膵外科学会学術集会, 2025年06月, 英語, 国内会議Prognosis of hepatectomy versus systemic chemotherapy based on oncological resectability criteria for borderline resectable hepatocellular carcinomaシンポジウム・ワークショップパネル（公募）
- 第37回日本肝胆膵外科学会学術集会, 2025年06月, 英語, 国内会議A case of laparoscopic distal pancreatectomy with misdissection of the portal vein and reconstruction with artificial vascular graft口頭発表（一般）
- 第61回日本肝臓学会総会, 2025年06月, 日本語, 国内会議大腸癌肝転移治療における全腫瘍体積の有用性の検討口頭発表（一般）
- 第61回日本肝臓学会総会, 2025年06月, 日本語, 国内会議アテゾリズマブ・ベバシズマブ併用療法後の根治を企図した粒子線治療の短期成績口頭発表（一般）
- 第61回日本肝臓学会総会, 2025年06月, 日本語, 国内会議アテゾリズマブ・ベバシズマブ併用療法後のチロシンキナーゼ阻害薬とデュルバルマブ・トレメリムマブ併用療法の治療成績に関する比較検討口頭発表（一般）
- 第61回日本肝臓学会総会, 2025年06月, 日本語, 国内会議切除不能肝細胞癌に対するアテゾリズマブ・ベバシズマブ併用療法リチャレンジの治療成績口頭発表（一般）
- 第61回日本肝臓学会総会, 2025年06月, 日本語, 国内会議進行肝細胞癌薬物療法における転移部位別奏効率の検討口頭発表（一般）
- 第197回兵庫県外科医会学術集会, 2025年05月, 日本語, 国内会議Frey術後の腹腔内遺残膵石が腹腔内腫瘍を形成した1例口頭発表（一般）
- 神経内分泌腫瘍を斬る！～""外科医の視点で考える"集学的治療のさらなる進化～, 2025年05月, 日本語, 国内会議外科的治療を中心とする集学的治療を行なった進行PanNETの1例口頭発表（一般）
- 第125回日本外科学会定期学術集会, 2025年04月, 日本語, 国内会議当科における吸収性スペーサー留置術 66 例の検討ポスター発表
- 第125回日本外科学会定期学術集会, 2025年04月, 日本語, 国内会議肝腫瘍のサイズが術後肝再生に与える影響ポスター発表
- 第125回日本外科学会定期学術集会, 2025年04月, 日本語, 国内会議胆道癌術後 S-1 術後補助化学療法施行例における GLIM 基準の予後因子としての有用性に関する検討ポスター発表
- 第125回日本外科学会定期学術集会, 2025年04月, 日本語, 国内会議PNI による術前栄養評価と肝細胞癌に対する肝切除の Textbook outcome および長期成績との関連性の検討ポスター発表
- 第125回日本外科学会定期学術集会, 2025年04月, 日本語, 国内会議高度門脈腫瘍栓合併肝細胞癌に対する肝切除術の意義ポスター発表
- 第125回日本外科学会定期学術集会, 2025年04月, 日本語, 国内会議胆道癌におけるアシアロシンチグラフィーを用いた術後肝不全予測ポスター発表
- 第125回日本外科学会定期学術集会, 2025年04月, 日本語, 国内会議重症例に対する肝移植のサステナビリティポスター発表
- 第125回日本外科学会定期学術集会, 2025年04月, 日本語, 国内会議当科における腫瘍学的切除可能性分類定義に基づいた肝切除・薬物療法成績の検討ポスター発表
- 第125回日本外科学会定期学術集会, 2025年04月, 日本語, 国内会議当科における大腸癌肝転移における治療戦略と術前化学療法の有用性ポスター発表
- 第125回日本外科学会定期学術集会, 2025年04月, 日本語, 国内会議当科における進行膵癌に対する Conversion Surgery の成績と課題ポスター発表
- 第125回日本外科学会定期学術集会, 2025年04月, 日本語, 国内会議肝細胞癌に対する肝右葉切除後の術後肝不全発症予測における肝予備能/線維化指標の有用性の比較ポスター発表
- 第125回日本外科学会定期学術集会, 2025年04月, 日本語, 国内会議肝門部領域胆管癌に対して門脈塞栓術後切除術を施行した症例の術後肝不全の検討ポスター発表
- 第125回日本外科学会定期学術集会, 2025年04月, 日本語, 国内会議非浸潤・微小浸潤 IPMN 切除後残膵再発に対する予定残膵の主膵管拡張の意義口頭発表（一般）
- 第125回日本外科学会定期学術集会, 2025年04月, 日本語, 国内会議肥満症例における右横隔膜下領域の肝切除に対する腹腔鏡アプローチの有用性口頭発表（一般）
- 第125回日本外科学会定期学術集会, 2025年04月, 日本語, 国内会議門脈合併切除を伴う膵癌切除術中の門脈/上腸間膜静脈断端の術中迅速診断の意義シンポジウム・ワークショップパネル（公募）
- 肝胆膵外科Webセミナー, 2025年03月, 日本語, 国内会議講演口頭発表（一般）
- 第52回日本膵・膵島移植学会学術集会, 2025年03月, 日本語, 国内会議当科における新規膵島実験室立ち上げの取り組み口頭発表（一般）
- 第208回近畿外科学会, 2025年03月, 日本語, 国内会議膵原発癌肉腫の 1 切除例口頭発表（一般）
- 第208回近畿外科学会, 2025年03月, 日本語, 国内会議Vp4 巨大肝細胞癌に対して経鼻経管栄養下に Durvalumab ＋ Tremelimumab 併用療法 を施行し conversion 肝切除が可能となった 1 例口頭発表（一般）
- 第208回近畿外科学会, 2025年03月, 日本語, 国内会議戸谷 IV-A 型先天性胆道拡張症に対するロボット支援下手術導入の経験口頭発表（一般）
- 第208回近畿外科学会, 2025年03月, 日本語, 国内会議座長その他
- 日本消化器病学会近畿支部第122回例会, 2025年02月, 日本語, 国内会議Frey術後の腹腔内遺残膵石が腹腔内腫瘍を形成した1例口頭発表（一般）
- 第40回日本栄養治療学会学術集会, 2025年02月, 日本語, 国内会議膵頭十二指腸切除術後のリポタンパク濃度の変化と臨床的意義シンポジウム・ワークショップパネル（公募）
- 第14回若手消化器外科腹腔鏡セミナー, 2025年01月, 日本語, 国内会議開会の挨拶その他
- 第31回日本肝がん分子標的治療研究会, 2025年01月, 日本語, 国内会議Vp3/4門脈腫瘍栓合併肝細胞癌に対するアテゾリズマブ・ベバシズマブ併用療法の治療成績口頭発表（一般）
- APA/JPS/CAP/IAP 2024, 2024年12月, 英語, 国内会議Impact of a dilated MPD in the expected remnant pancreas on recurrence after resection of non-/micro-invasive IPMN口頭発表（一般）
- APA/JPS/CAP/IAP 2024, 2024年12月, 英語, 国内会議Comprehensive analysis of altered lipid and amino acid metabolism in patients undergoing pancreatoduodenectomy口頭発表（一般）
- 第37回日本内視鏡外科学会総会（JSES2024）, 2024年12月, 日本語, 国内会議胆嚢摘出既往のある再肝切除症例における腹腔鏡アプローチの有用性に関する検討口頭発表（一般）
- 第37回日本内視鏡外科学会総会（JSES2024）, 2024年12月, 日本語, 国内会議Fontan循環における腹腔鏡下肝切除術の経験口頭発表（一般）
- 第37回日本内視鏡外科学会総会（JSES2024）, 2024年12月, 日本語, 国内会議3Dシミュレーション画像は真のリアルタイムナビゲーションになっているか？シンポジウム・ワークショップパネル（公募）
- 第37回日本内視鏡外科学会総会（JSES2024）, 2024年12月, 日本語, 国内会議膵癌に対する腹腔鏡下膵体尾部切除術の短期・長期成績に関する検討シンポジウム・ワークショップパネル（公募）
- 第37回日本内視鏡外科学会総会（JSES2024）, 2024年12月, 日本語, 国内会議40歳肝胆膵外科医の腹腔鏡下膵切除の実際シンポジウム・ワークショップパネル（公募）
- 第37回日本内視鏡外科学会総会（JSES2024）, 2024年12月, 日本語, 国内会議ロボット支援下膵切除導入の経験とフィードバックシンポジウム・ワークショップパネル（公募）
- 第11回神戸肝胆膵外科ビデオクリニック, 2024年11月, 日本語, 国内会議司会（第2部）その他
- 第86回日本臨床外科学会総会, 2024年11月, 日本語, 国内会議腹腔鏡下肝切除技術認定取得への道シンポジウム・ワークショップパネル（公募）
- 第66回日本消化器病学会大会（JDDW2024）, 2024年10月, 英語, 国内会議Postoperative complications assessed by the comprehensive complication index (CCI) are associated with early recurrence after curative resection for biliary tract cancerポスター発表
- 第22回日本消化器外科学会（JDDW2024）, 2024年10月, 日本語, 国内会議吸収性スペーサー併用粒子線治療後に局所再発した後腹膜平滑筋肉腫に対して2回目の吸収性スペーサー留置術および粒子線治療を行った1例ポスター発表
- 第22回日本消化器外科学会（JDDW2024）, 2024年10月, 日本語, 国内会議左側門脈圧亢進症に対する門脈ステントの有用性についてポスター発表
- 第22回日本消化器外科学会（JDDW2024）, 2024年10月, 日本語, 国内会議胆道癌術後S-1術後補助療法施行例におけるGLIM基準の予後因子としての有用性に関する検討ポスター発表
- 第22回日本消化器外科学会（JDDW2024）, 2024年10月, 日本語, 国内会議胆道癌に対するS-1術後補助化学療法と術後早期再発との関連ポスター発表
- 第22回日本消化器外科学会（JDDW2024）, 2024年10月, 日本語, 国内会議膵頭十二指腸切除術後の血中必須脂肪酸の推移およびPD後NAFLDとの関係ポスター発表
- 第22回日本消化器外科学会（JDDW2024）, 2024年10月, 日本語, 国内会議膵癌術後再発病変に対する外科的切除は予後延長に寄与するのかポスター発表
- 第22回日本消化器外科学会（JDDW2024）, 2024年10月, 日本語, 国内会議主要脈管近接腫瘍に対する腹腔鏡下Parenchymal-sparing hepatectomyポスター発表
- 第22回日本消化器外科学会（JDDW2024）, 2024年10月, 日本語, 国内会議肝細胞癌症例における肝切除術後胆汁漏の予後への影響についての検討ポスター発表
- 第47回日本膵・胆管合流異常研究会, 2024年09月, 日本語, 国内会議膵・胆管合流異常に合併した2型 IPNB に相当する胆嚢内乳頭状腫瘍の1例口頭発表（一般）
- ELSA2024, 2024年08月, 英語, 国内会議Optimal cutoff values of drain amylase for predicting pancreatic fistula are different between open and laparoscopic distal pancreatectomy口頭発表（一般）
- 第55回日本膵臓学会大会, 2024年07月, 日本語, 国内会議局所進行切除不能膵癌に対するスペーサー留置術後の陽子線治療の成績と展望口頭発表（一般）
- 第55回日本膵臓学会大会, 2024年07月, 日本語, 国内会議膵癌に対する膵切除術における膵断端の癌遺残に関する検討シンポジウム・ワークショップパネル（公募）
- 第55回日本膵臓学会大会, 2024年07月, 日本語, 国内会議膵頭十二指腸切除術後の脂質アミノ酸代謝の変化の解明シンポジウム・ワークショップパネル（公募）
- The 14th Asia-Pacific Primary Liver Cancer Expert Meeting 2024 (APPLE), 2024年07月, 英語, 国内会議Textbook outcomes in initial liver resection for hepatocellular carcinoma: a study with malnutrition grade by the GLIM criteria.ポスター発表
- 第79回日本消化器外科学会総会, 2024年07月, 日本語, 国内会議80 歳以上の高齢膵癌患者に対する膵頭十二指腸切除術の短期成績と長期成績について口頭発表（一般）
- 第79回日本消化器外科学会総会, 2024年07月, 日本語, 国内会議消化器外科医夫婦がキャリア形成を続けるためにした工夫口頭発表（一般）
- 第79回日本消化器外科学会総会, 2024年07月, 日本語, 国内会議膵頭十二指腸切除術後の脂肪肝発症とその生理学的機序解明の試み口頭発表（一般）
- 第79回日本消化器外科学会総会, 2024年07月, 日本語, 国内会議局所進行膵癌に対する動脈剥離手技と動脈・門脈再建手技口頭発表（一般）
- 第60回日本肝癌研究会, 2024年07月, 日本語, 国内会議肝細胞癌における肝切除術後胆汁漏関連因子の予後への影響に関する検討口頭発表（一般）
- 第36回日本肝胆膵外科学会・学術集会, 2024年06月, 英語, 国内会議Short- and long-term outcomes after pancreatectomy for pancreatic cancer in octogenarianシンポジウム・ワークショップパネル（公募）
- 第36回日本肝胆膵外科学会・学術集会, 2024年06月, 英語, 国内会議Our Surgical Techniques for Pancreatic Cancer with Arterial Contact口頭発表（一般）
- 第36回日本肝胆膵外科学会・学術集会, 2024年06月, 英語, 国内会議Nightmare for a 16-year-old man who presented with undiagnosed severe diabetes-induced NOMI and required a total pancreatectomy and massive enterectomy口頭発表（一般）
- 第36回日本肝胆膵外科学会・学術集会, 2024年06月, 英語, 国内会議Optimal approaches to minimize complications in pancreas transplantationシンポジウム・ワークショップパネル（公募）
- 第46回日本癌局所療法研究会, 2024年06月, 日本語, 国内会議腹腔鏡下膵頭十二指腸切除術で R0 手術となった胆管原発神経内分泌癌の1切除例口頭発表（一般）
- 第60回日本肝臓学会総会, 2024年06月, 日本語, 国内会議切除不能肝細胞癌に対するアテゾリズマブ/ベバシズマブ併用療法の治療効果と全腫瘍体積の関連性についての検討口頭発表（一般）
- EAES2024, 2024年06月, 英語, 国内会議Laparoscopic SM0 liver resection for hepatocellular carcinoma adjacent to the hepatic hilumポスター発表
- 第110回日本消化器病学会総会, 2024年05月, 日本語, 国内会議大腸癌肝転移におけるRAS遺伝子情報と肝転移巣局在の関連性口頭発表（一般）
- 第124回日本外科学会定期学術集会, 2024年04月, 日本語, 国内会議当科における吸収性スペーサー留置術 45 例の検討ポスター発表
- 第124回日本外科学会定期学術集会, 2024年04月, 日本語, 国内会議胆道癌術後 S-1 術後補助療法施行例における GLIM 基準の予後因子としての有用性に関する検討ポスター発表
- 第124回日本外科学会定期学術集会, 2024年04月, 日本語, 国内会議胆道癌における再発時期と再発様式についての検討ポスター発表
- 第124回日本外科学会定期学術集会, 2024年04月, 日本語, 国内会議肝切除における術中超音波胆道造影法を併用したリークテストの有用性ポスター発表
- 第124回日本外科学会定期学術集会, 2024年04月, 日本語, 国内会議外科医が長く働き続けられるための当院での取り組みポスター発表
- 第124回日本外科学会定期学術集会, 2024年04月, 日本語, 国内会議肝門部胆管癌における術後肝不全・難治性腹水ポスター発表
- 第124回日本外科学会定期学術集会, 2024年04月, 日本語, 国内会議大腸癌肝転移における切除後再発リスク分類と集学的治療戦略ポスター発表
- 第124回日本外科学会定期学術集会, 2024年04月, 日本語, 国内会議肝細胞癌に対する肝右葉切除後における術後肝不全発症の危険因子の検討ポスター発表
- 第124回日本外科学会定期学術集会, 2024年04月, 日本語, 国内会議肥満症例での肝 S7 切除における腹腔鏡下アプローチのメリットについてポスター発表
- 第124回日本外科学会定期学術集会, 2024年04月, 日本語, 国内会議高齢遠位胆管癌患者に対する高難度手術成績の検討ポスター発表
- 第124回日本外科学会定期学術集会, 2024年04月, 日本語, 国内会議進行胆道癌に対する Conversion surgeryポスター発表
- 第124回日本外科学会定期学術集会, 2024年04月, 日本語, 国内会議胆道癌に対する膵頭十二指腸切除術における GLIM 基準低栄養が術後合併症へ与える影響の検討口頭発表（一般）
- 第124回日本外科学会定期学術集会, 2024年04月, 日本語, 国内会議膵頭十二指腸切除術後外分泌不全に対する治療バイオマーカーの探索口頭発表（一般）
- 第124回日本外科学会定期学術集会, 2024年04月, 日本語, 国内会議開腹および腹腔鏡下膵体尾部切除のドレーンアミラーゼ値による適切なドレーン管理の検討口頭発表（一般）
- 日本ERAS®学会第2回学術集会, 2024年04月, 日本語, 国内会議ERAS プロトコルの術前経口補水に分枝鎖アミノ酸飲料は有用か？口頭発表（一般）
- The 33rd Annual Meeting the Asian Pacific Association for the Study of the Liver (APASL2024), 2024年03月, 英語, 国内会議Utility of ALBI grade for predicting prognoses in patients who underwent repeat hepatectomyポスター発表
- The 33rd Annual Meeting the Asian Pacific Association for the Study of the Liver (APASL2024), 2024年03月, 英語, 国内会議A comparative study of laparoscopic liver resection for the segment 4 superior and inferior area口頭発表（一般）
- The 33rd Annual Meeting the Asian Pacific Association for the Study of the Liver (APASL2024), 2024年03月, 英語, 国内会議The Efficacy of Total Tumor Volume in Patients with Colorectal Liver Metastases口頭発表（一般）
- 第10回神戸肝胆膵外科ビデオクリニック, 2024年03月, 日本語, 国内会議第1部「内視鏡技術認定医提出ビデオ」口頭発表（一般）
- 第51回近畿肝臓外科研究会, 2024年02月, 日本語, 国内会議主要脈管近接腫瘍に対する腹腔鏡下肝切除口頭発表（一般）
- 第39回日本臨床栄養代謝学会学術集会（JSPEN2024）, 2024年02月, 日本語, 国内会議質量分析計を用いた膵頭十二指腸切除術後外分泌不全に対する治療バイオマーカーの探索シンポジウム・ワークショップパネル（公募）
- 日本消化器病学会近畿支部第120回例会, 2024年01月, 日本語, 国内会議胆道再建既往の肝切除症例における術後感染性合併症口頭発表（一般）
- 日本消化器病学会近畿支部第120回例会, 2024年01月, 日本語, 国内会議GLIM基準低栄養は胆道癌に対する膵頭十二指腸切除術後合併症リスクを増加させる口頭発表（一般）
- 日本消化器病学会近畿支部第120回例会, 2024年01月, 日本語, 国内会議門脈輪状膵症例に対するロボット支援下膵頭十二指腸切除術の1例シンポジウム・ワークショップパネル（公募）
- 第36回日本内視鏡外科学会総会, 2023年12月, 日本語, 国内会議腹腔鏡下肝 S8 部分切除術における背側領域と腹側領域での手術成績比較口頭発表（一般）
- 第36回日本内視鏡外科学会総会, 2023年12月, 日本語, 国内会議肝門部に近接する肝細胞癌に対する腹腔鏡下肝部分切除術口頭発表（一般）
- 第36回日本内視鏡外科学会総会, 2023年12月, 日本語, 国内会議当科における肝 S1 病変に対する腹腔鏡手術の有効性と安全性の検討口頭発表（一般）
- 第36回日本内視鏡外科学会総会, 2023年12月, 日本語, 国内会議肝臓外科におけるロボット支援化手術導入への悩み口頭発表（一般）
- 第45回日本肝臓学会西部会, 2023年12月, 日本語, 国内会議肝細胞癌再発に対してラムシルマブ長期投与が可能であった1例口頭発表（一般）
- 第45回日本肝臓学会西部会, 2023年12月, 日本語, 国内会議肝予備能不良な肝細胞癌に対して吸収性スペーサー留置後に陽子線治療を施行し腫瘍制御が得られた1例口頭発表（一般）
- Transplantation Science Symposium(TSS) Asian Regional Meeting 2022, 2023年11月, 英語, 国際会議Chair(Mini Oral 30)その他
- 第44回日本肝臓学会東部会, 2023年11月, 日本語, 国内会議粒子線治療適応拡大を可能とする新規素材吸収性スペーサーの開発と臨床応用した肝細胞癌の 1 例口頭発表（一般）
- 第44回日本肝臓学会東部会, 2023年11月, 日本語, 国内会議肝S8領域に生じた肝細胞癌に対する腹腔鏡下肝切除術の有効性に関する検討口頭発表（一般）
- 第44回日本肝臓学会東部会, 2023年11月, 日本語, 国内会議初回再発形式からみる肝細胞癌の腫瘍位置と初回再発形式に関する検討口頭発表（一般）
- 第26回近畿膵移植検討会, 2023年11月, 日本語, 国内会議膵島移植と異種抗原口頭発表（一般）
- 第85回日本臨床外科学会総会, 2023年11月, 日本語, 国内会議吸収性スペーサー留置術35例の検討口頭発表（一般）
- 第15回膵臓内視鏡外科研究会, 2023年11月, 日本語, 国内会議ロボット支援下膵手術における剥離・切離法の試行錯誤口頭発表（一般）
- 第15回膵臓内視鏡外科研究会, 2023年11月, 日本語, 国内会議ロボット支援下膵頭十二指腸切除を行った門脈輪状膵の１例ポスター発表
- 第65回日本消化器病学会大会（JDDW2023), 2023年11月, 日本語, 国内会議胆道癌における再発時期と再発形式の検討ポスター発表
- 第21回日本消化器外科学会大会（JDDW2023）, 2023年11月, 日本語, 国内会議肝外胆管癌における術前骨格筋量減少の術後早期再発への影響ポスター発表
- 第21回日本消化器外科学会大会（JDDW2023）, 2023年11月, 日本語, 国内会議吸収性スペーサー留置術33例の検討ポスター発表
- 第21回日本消化器外科学会大会（JDDW2023）, 2023年11月, 日本語, 国内会議局所進行切除不能膵癌に対するスペーサー留置術後の陽子線治療の有用性についてポスター発表
- 第21回日本消化器外科学会大会（JDDW2023）, 2023年11月, 日本語, 国内会議肝門部胆管癌術後の術後胆汁漏の検討ポスター発表
- 第21回日本消化器外科学会大会（JDDW2023）, 2023年11月, 日本語, 国内会議肝切除術後の門脈血栓症に対するエドキサバンの治療成績ポスター発表
- 第21回日本消化器外科学会大会（JDDW2023）, 2023年11月, 日本語, 国内会議膵癌術後再発に対する治療戦略の現状と展望ポスター発表
- 第21回日本消化器外科学会大会（JDDW2023）, 2023年11月, 日本語, 国内会議初回肝切除への腹腔鏡アプローチ適応による再肝切除時のメリットについてポスター発表
- 第21回日本消化器外科学会大会（JDDW2023）, 2023年11月, 日本語, 国内会議当院における術後胆管狭窄症例に対する対応と検討ポスター発表
- 第21回日本消化器外科学会大会（JDDW2023）, 2023年11月, 日本語, 国内会議肝外胆管癌切除後S-1補助化学療法例におけるGLIM基準の有用性に関する検討ポスター発表
- 第58回日本移植学会総会, 2023年10月, 日本語, 国内会議移植後非結核性抗酸菌症治療中にCOVID-19を発症した一例口頭発表（一般）
- 7th Kansai-Yeungnam HBP Surgeons Meeting, 2023年10月, 英語, 国際会議Proton radiotherapy as a treatment strategy to increase survival in locally advanced pancreatic cancer in the body and tail: a retrospective studyポスター発表
- 7th Kansai-Yeungnam HBP Surgeons Meeting, 2023年10月, 英語, 国際会議Risk Factors for Recurrence of Cholangitis After Pancreaticoduodenectomy and Comparison of Stents in Hepaticojejunostomyポスター発表
- 第14回日本Acute Care Surgery学会学術集会, 2023年09月, 日本語, 国内会議がん化学療法中の急性胆嚢炎症例の検討ポスター発表
- 第59回日本移植学会総会, 2023年09月, 日本語, 国内会議脳死肝移植・肝グラフト採取術手技習得における Cadaver Surgical Training の有用性口頭発表（一般）
- 第59回日本移植学会総会, 2023年09月, 日本語, 国内会議次世代継承、肝移植のススメ口頭発表（一般）
- 第59回日本胆道学会学術集会, 2023年09月, 日本語, 国内会議当科で経験した無石性胆嚢炎症例の臨床像ポスター発表
- 第59回日本胆道学会学術集会, 2023年09月, 日本語, 国内会議胆道癌に対するS-1術後補助化学療法と再発時期の関連ポスター発表
- 第59回日本胆道学会学術集会, 2023年09月, 日本語, 国内会議IPMNに併存した十二指腸乳頭部上皮内癌の1例ポスター発表
- 4th World Congress of International Laparoscopic liver Society（ILLS）, 2023年09月, 英語, 国際会議A comparative study of laparo-scopic liver resection for the segment 8 dorsal and ventral areaポスター発表
- 45th ESPEN Congress, 2023年09月, 英語, 国際会議Impact of malnutrition diagnosed by the GLIM criteria on postoperative complications after pancreaticoduodenectomy for biliary tract cancerポスター発表
- 45th ESPEN Congress, 2023年09月, 英語, 国際会議Impact of malnutrition diagnosed by the GLIM criteria on outcome of elderly patients with hepatocellular carcinoma after liver resectionポスター発表
- 第46回日本膵・胆管合流異常研究会, 2023年09月, 日本語, 国内会議膵・胆管合流異常に発生した膵管内乳頭粘液性腺癌の1切除例口頭発表（一般）
- 第45回日本膵・胆管合流異常研究会, 2023年09月, 日本語, 国内会議胆管非拡張型膵・胆管合流異常に対する胆嚢摘出後の胆管径の変化に関する検討（第2報）口頭発表（一般）
- APASL Oncology 2022, 2023年09月, 英語, 国際会議Hepatic Resection versus Particle Therapy for Single Hepatocellular Carcinoma as An Initial Treatment: A Multicenter Propensity Score Matched Analysisポスター発表
- 第54回日本膵臓学会大会, 2023年07月, 日本語, 国内会議当院における膵神経内分泌腫瘍のバイオマーカー探索の試みシンポジウム・ワークショップパネル（公募）
- 第54回日本膵臓学会大会, 2023年07月, 日本語, 国内会議高齢者に対する膵全摘, 残膵全摘の短期・長期成績についてシンポジウム・ワークショップパネル（公募）
- 第54回日本膵臓学会大会, 2023年07月, 日本語, 国内会議Solid - pseudopapillary neoplasm（SPN）に対する至適術式シンポジウム・ワークショップパネル（公募）
- 第78回日本消化器外科学会総会, 2023年07月, 日本語, 国内会議膵頭十二指腸切除術前後の血中必須脂肪酸の推移口頭発表（一般）
- 第78回日本消化器外科学会総会, 2023年07月, 日本語, 国内会議切除可能膵癌に対する術前化学療法症例の成績と問題点口頭発表（一般）
- 第78回日本消化器外科学会総会, 2023年07月, 日本語, 国内会議腹腔鏡下膵頭十二指腸切除の導入と定型化への工夫口頭発表（一般）
- 第78回日本消化器外科学会総会, 2023年07月, 英語, 国内会議Preoperative serum transthyretin level predicts survival in PDAC patients receiving pancreatectomyシンポジウム・ワークショップパネル（公募）
- 第35回日本肝胆膵外科学会学術集会, 2023年06月, 英語, 国内会議A study for infectious complication of hepatectomies in patients with preexisting bilioenteric anastomosisポスター発表
- 第35回日本肝胆膵外科学会学術集会, 2023年06月, 英語, 国内会議Intracholecystic papillary neoplasm (ICPN) with pancreaticobiliary maljunction (PBM): Comparison with normal gallbladder cancer with PBMポスター発表
- 第35回日本肝胆膵外科学会学術集会, 2023年06月, 英語, 国内会議Successful biliary drainage using hybrid EUS-BD for stricture of choledochojejunostomyポスター発表
- 第35回日本肝胆膵外科学会学術集会, 2023年06月, 英語, 国内会議Intended destination for a board certified surgeon under 45口頭発表（一般）
- 第35回日本肝胆膵外科学会学術集会, 2023年06月, 英語, 国内会議Prognostic significance of malnutrition diagnosed by the GLIM criteria for resected extrahepatic cholangiocarcinoma: A single-center retrospective study口頭発表（一般）
- 第35回日本肝胆膵外科学会学術集会, 2023年06月, 英語, 国内会議Improvement in stapler pancreatic transection to reduce pancreatic fistula after laparoscopic distal pancreatectomy: twelve-year experience at a single high-volume center口頭発表（一般）
- 第35回日本肝胆膵外科学会学術集会, 2023年06月, 英語, 国内会議Reappraisal of malignant risk assessment for small (≦20 mm) non-functioning pancreatic neuroendocrine tumorsシンポジウム・ワークショップパネル（公募）
- 第35回日本肝胆膵外科学会学術集会, 2023年06月, 英語, 国内会議Anterior approach for open rigththepatectomy for huge hepatocellular carcinomaシンポジウム・ワークショップパネル（公募）
- 第35回日本肝胆膵外科学会学術集会, 2023年06月, 英語, 国内会議Our surgical technique of vascular dissection and resection for locally advanced pancreatic cancerシンポジウム・ワークショップパネル（公募）
- 第59回日本肝臓学会総会, 2023年06月, 日本語, 国内会議切除不能肝内胆管癌に対する粒子線治療の成績口頭発表（一般）
- 第68回国際外科学会日本部会総会, 2023年06月, 英語, 国際会議Investigation of the relationship between complications after pancreaticoduodenectomy for distal cholangiocarcinoma and malnutrition diagnosed by the GLIM criteria口頭発表（一般）
- 第45回日本癌局所療法研究会, 2023年06月, 日本語, 国内会議腹腔動脈狭窄を伴う十二指腸乳頭部癌に対し膵頭十二指腸切除術を施行した１例口頭発表（一般）
- 第41回日本肝移植学会学術集会, 2023年06月, 日本語, 国内会議脳死肝移植に初めて参加した経験から得られた移植医療に対する抱負口頭発表（一般）
- 第41回日本肝移植学会学術集会, 2023年06月, 日本語, 国内会議当科における MELD スコア制導入後の脳死肝移植希望登録患者に関する検討シンポジウム・ワークショップパネル（公募）
- 第38回日本臨床栄養代謝学会学術集会, 2023年05月, 日本語, 国内会議膵頭十二指腸切除術前後の血中必須脂肪酸の推移口頭発表（一般）
- 第38回日本臨床栄養代謝学会学術集会, 2023年05月, 日本語, 国内会議膵術前の血清亜鉛値と胆道ドレナージが及ぼす影響口頭発表（一般）
- 第38回日本臨床栄養代謝学会学術集会, 2023年05月, 日本語, 国内会議肝細胞癌肝切除症例における GLIM 基準を用いた術前低栄養診断の意義口頭発表（一般）
- 第38回日本臨床栄養代謝学会学術集会, 2023年05月, 日本語, 国内会議肝外胆管癌術後早期再発リスク因子としての GLIM 基準で診断した術前低栄養に関する観察研究口頭発表（一般）
- 第38回日本臨床栄養代謝学会学術集会, 2023年05月, 日本語, 国内会議膵癌患者における術前プレアルブミン値は術後予後予測に有用であるシンポジウム・ワークショップパネル（公募）
- 第123回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議肝外胆管癌切除後の早期再発予測におけるGLIM基準の有用性ポスター発表
- 第123回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議大腸癌肝転移における予後予測因子としての全腫瘍体積の有用性と，適切な化学療法導入時期に関する観察研究ポスター発表
- 第123回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議当科における吸収性スペーサー留置術22例の臨床経過ポスター発表
- 第123回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議術前化学療法後に切除を施行したBR-A膵癌，UR-LA膵癌における早期再発risk因子の検討ポスター発表
- 第123回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議胆道癌における術後静脈血栓症と血漿Dダイマーの関連性の検討ポスター発表
- 第123回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議術前NLR値と胆嚢癌の予後との関連ポスター発表
- 第123回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議肝細胞癌切除症例におけるGLIM基準と予後の関連ポスター発表
- 第123回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議十二指腸乳頭部癌におけるC-reactive protein to albumin ratio（CAR）の予後への影響ポスター発表
- 第123回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議右肝葉切除を施行した肝門部領域胆管癌の再考；左側からの切除の可能性ポスター発表
- 第123回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議治療成績から見た大腸癌肝転移における切除可能性分類と治療戦略ポスター発表
- 第123回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議肝門部領域胆管癌に対する術前門脈塞栓術施行例の検討ポスター発表
- 第123回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議肝移植後長期成績向上のために，何が必要かポスター発表
- 第123回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議局所進行膵癌に対する外科治療ポスター発表
- 第123回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議肝外胆管癌切除後予後因子としてのGLIM基準の有用性に関する検討ポスター発表
- 第123回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議ロボット支援下膵体尾部切除導入期に直面する技術的問題点ポスター発表
- 第123回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議胆道癌に対するS-1術後補助化学療法と早期再発の関連口頭発表（一般）
- 第123回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議Under 40外科医が専門医取得の次に目指すものシンポジウム・ワークショップパネル（公募）
- 第123回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議初回再発形式からみる表在性肝細胞癌に対する非系統的切除術の妥当性に関する検討シンポジウム・ワークショップパネル（公募）
- 第123回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議膵癌患者における術前低栄養の評価とその臨床的役割シンポジウム・ワークショップパネル（公募）
- 第108回日本消化器病学会総会, 2023年04月, 日本語, 国内会議肝移植後の経時的体重変化を予測する因子に関する検討口頭発表（一般）
- 第108回日本消化器病学会総会, 2023年04月, 日本語, 国内会議高度進行肝細胞癌に対する集学的アプローチ口頭発表（一般）
- 第122回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議当院における切除不能肝細胞癌に対するレンバチニブの治療成績ポスター発表
- 第122回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議膵頭十二指腸切除後患者に対するアミノ酸製剤を用いた術後栄養療法の有用性ポスター発表
- 第122回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議当院における術前補助療法後に切除を施行したBR膵癌と conversion 手術を施行した UR-LA 膵臓の治療成績の比較ポスター発表
- 第122回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議肝胆道癌における肝切除後静脈血栓塞栓症とDダイマーの関連性の検討ポスター発表
- 第122回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議高度進行肝細胞癌に対し減量肝切除を実施した症例におけるサルコペニアと予後に関する検討ポスター発表
- 第122回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議膵癌における術前 Rapid Turnover Protein 測定の臨床的役割ポスター発表
- 第122回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議若年性膵癌症例の検討ポスター発表
- 第122回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議膵切除後血漿 D-dimer の推移と術後静脈血栓症診断における意義口頭発表（一般）
- 第122回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議大腸癌肝転移における予後予測因子としての全腫瘍体積の有用性に関する検討口頭発表（一般）
- 第122回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議当院における切除不能肝細胞癌に対するラムシルマブ治療成績の検討口頭発表（一般）
- 第122回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議膵頭十二指腸切除術後の早期胆管炎リスク因子の検討口頭発表（一般）
- 第122回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議肝細胞癌の腫瘍位置と初回再発形式に関する検討口頭発表（一般）
- 第122回日本外科学会定期学術集会, 2023年04月, 日本語, 国内会議肝細胞癌における肝右葉切除術後1日目のC反応性蛋白低値は術後肝不全発症の早期予測に有用である口頭発表（一般）
- 第109回日本消化器病学会総会, 2023年04月, 日本語, 国内会議食道胃静脈瘤に対するHassab手術が術後肝機能に与える影響についての検討口頭発表（一般）
- 第109回日本消化器病学会総会, 2023年04月, 日本語, 国内会議術前骨格筋量減少が肝外胆管癌切除後の長期予後に与える影響に関する観察研究口頭発表（一般）
- 第109回日本消化器病学会総会, 2023年04月, 日本語, 国内会議肝胆膵領域におけるAIを用いた手術支援技術の現状と展望口頭発表（一般）
- 15th World Congress of the International Hepato-Pancreato-Biliary Association (IHPBA), 2023年03月, 英語, 国際会議Intraoperative Assessment of the Demarcation Line and Intersegmental/Sectional Planes in Liver Surgeryポスター発表
- 第59回日本腹部救急医学会総会, 2023年03月, 日本語, 国内会議当科における無石性胆嚢炎症例の手術成績口頭発表（一般）
- 第59回日本腹部救急医学会総会, 2023年03月, 日本語, 国内会議膵尾側温存の意義シンポジウム・ワークショップパネル（公募）
- 第50回近畿肝臓外科研究会, 2023年01月, 日本語, 国内会議当科肝臓外科における術中ナビゲーションの現状と展望口頭発表（一般）
- 第39回近畿肝移植検討会, 2022年12月, 日本語, 国内会議脳死肝移植登録待機中管理に難渋した一例口頭発表（一般）
- Asian-Pacific Congress of Robotic Laparoscopic Surgery 2022 (ACRLS 2022), 2022年12月, 英語, 国際会議Laparoscopic anatomical resection of segment 2 by Glissonean approach口頭発表（一般）
- 第35回日本内視鏡外科学会総会, 2022年12月, 日本語, 国内会議当院における腹腔鏡下膵頭十二指腸切除の導入口頭発表（一般）
- 第35回日本内視鏡外科学会総会, 2022年12月, 日本語, 国内会議ロボット支援膵切除時代における技術認定制度の役割と問題点シンポジウム・ワークショップパネル（公募）
- 第14回膵臓内視鏡外科研究会, 2022年11月, 日本語, 国内会議ロボット支援下膵体尾部切除導入期に直面する諸問題シンポジウム・ワークショップパネル（公募）
- 第14回膵臓内視鏡外科研究会, 2022年11月, 日本語, 国内会議門脈輪状膵を併存した症例に対する腹腔鏡下膵切除術の経験口頭発表（一般）
- 第14回膵臓内視鏡外科研究会, 2022年11月, 日本語, 国内会議腹腔鏡下膵体尾部切除術の膵頚部切離における 45mm カートリッジの有用性シンポジウム・ワークショップパネル（公募）
- 第35回日本外科感染症学会総会学術集会, 2022年11月, 日本語, 国内会議胆道癌に対する術前胆汁返還の SSI に対する意義シンポジウム・ワークショップパネル（公募）
- JDDDW2022, 2022年10月, 英語, 国内会議The usefulness of total tumor volume as a prognostic factor with colorectal cancer liver metastasesポスター発表
- 第20回消化器外科学会大会（JDDW2022）, 2022年10月, 日本語, 国内会議肝S8病変に対する腹腔鏡下肝切除術適応の有効性ポスター発表
- 第20回消化器外科学会大会（JDDW2022）, 2022年10月, 日本語, 国内会議肝切除後の術後静脈血栓塞栓症の発症における予測スコアの有用性の検討ポスター発表
- 第20回消化器外科学会大会（JDDW2022）, 2022年10月, 日本語, 国内会議膵頭十二指腸切除術後の早期胆管炎リスク因子の検討ポスター発表
- 第20回消化器外科学会大会（JDDW2022）, 2022年10月, 日本語, 国内会議再発形式からみる表在性肝細胞癌に対する非解剖学的切除術の妥当性の検討ポスター発表
- 第20回消化器外科学会大会（JDDW2022）, 2022年10月, 日本語, 国内会議初発単発肝細胞癌に対する肝切除と粒子線治療成績の比較検討ポスター発表
- 第20回消化器外科学会大会（JDDW2022）, 2022年10月, 日本語, 国内会議胆嚢癌におけるInflammation-based prognostic scoresの予後への影響ポスター発表
- 第20回消化器外科学会大会（JDDW2022）, 2022年10月, 日本語, 国内会議局所進行切除不能膵癌に対する粒子線治療の成績とスペーサー留置術の有用性についてポスター発表
- 第20回消化器外科学会大会（JDDW2022）, 2022年10月, 日本語, 国内会議血清D-dimer値を用いた膵切除後静脈血栓症予測ポスター発表
- 第20回消化器外科学会大会（JDDW2022）, 2022年10月, 日本語, 国内会議食道癌術後の膵癌に対する膵切除6例の検討ポスター発表
- 第20回消化器外科学会大会（JDDW2022）, 2022年10月, 日本語, 国内会議肝動脈化学塞栓療法を中心とした膵神経内分泌腫瘍肝転移に対する集学的治療ポスター発表
- 第20回消化器外科学会大会（JDDW2022）, 2022年10月, 日本語, 国内会議肝細胞癌に対するmajor hepatectomy後の術後肝不全発症早期予測における術後1日目CRP低値の有用性ポスター発表
- 第20回消化器外科学会大会（JDDW2022）, 2022年10月, 日本語, 国内会議肝S7切除における腹腔鏡手術と開腹手術の手術成績の比較ポスター発表
- 第20回消化器外科学会大会（JDDW2022）, 2022年10月, 日本語, 国内会議胆管癌の術後早期再発症例の検討ポスター発表
- 第20回消化器外科学会大会（JDDW2022）, 2022年10月, 日本語, 国内会議非乳頭部十二指腸癌に対する手術成績ポスター発表
- 第20回消化器外科学会大会（JDDW2022）, 2022年10月, 日本語, 国内会議腹腔鏡下膵体尾部切除における45mmカートリッジを用いた膵切離ポスター発表
- 第64回消化器病学会大会（JDDW2022）, 2022年10月, 日本語, 国内会議Intermediate HCCに対する集学的アプローチポスター発表
- 第26回肝臓学会大会（JDDW2022）, 2022年10月, 日本語, 国内会議ポストコロナ時代における急性肝不全に対する移植医療ポスター発表
- 第60回癌治療学会学術集会, 2022年10月, 日本語, 国内会議神戸大学における肝癌集学的治療の現状シンポジウム・ワークショップパネル（公募）
- 日本蛍光ガイド手術研究会第５回学術集会, 2022年09月, 日本語, 国内会議ICG蛍光法を用いた腹腔鏡下肝S2亜区域切除術シンポジウム・ワークショップパネル（公募）
- 第77回日本消化器外科学会総会, 2022年07月, 日本語, 国内会議腹腔鏡で診断しえた膵癌EUS-FNA後のNeedle Tract Seedingの1例口頭発表（一般）
- 第77回日本消化器外科学会総会, 2022年07月, 日本語, 国内会議当院での切除可能膵癌患者に対する治療成績口頭発表（一般）
- 第77回日本消化器外科学会総会, 2022年07月, 日本語, 国内会議脾動静脈根部に近接する膵体部癌に対する腹腔鏡下膵体尾部切除口頭発表（一般）
- 第77回日本消化器外科学会総会, 2022年07月, 英語, 国内会議Our surgical technique of vascular resection for locally advanced pancreatic cancerシンポジウム・ワークショップパネル（公募）
- 第77回日本消化器外科学会総会, 2022年07月, 英語, 国内会議Preoperative HbA1c and transthyretin concentrations predict survival after total pancreatectomyシンポジウム・ワークショップパネル（公募）
- 第53回日本膵臓学会大会・第26回国際膵臓学会, 2022年07月, 英語, 国内会議Survival outcome of chemotherapy-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer口頭発表（一般）
- 第53回日本膵臓学会大会・第26回国際膵臓学会, 2022年07月, 英語, 国内会議Diagnosis and treatment strategy of patients with early-stage(Stage 0/IA) pancreatic cancer口頭発表（一般）
- 第53回日本膵臓学会大会・第26回国際膵臓学会, 2022年07月, 英語, 国内会議Prediction of diabetes outcome in recipients of total pancreatectomy and islet autotransplantationシンポジウム・ワークショップパネル（公募）
- 第53回日本膵臓学会大会・第26回国際膵臓学会, 2022年07月, 英語, 国内会議Our standardized technique of laparoscopic distal pancreatectomy for pancreatic cancerシンポジウム・ワークショップパネル（公募）
- 第40回日本肝移植学会学術集会, 2022年07月, 日本語, 国内会議当施設における脳死下臓器摘出時互助制度の現状と課題シンポジウム・ワークショップパネル（公募）
- 30th International Congress of the European Association for Endoscopic Surgery （EAES2022）, 2022年07月, 英語, 国際会議Standardization of laparoscopic anatomic liver resection of segment 2 by glissonean approach口頭発表（一般）
- 第47回日本外科系連合学会学術集会, 2022年06月, 日本語, 国内会議当科における吸収性スペーサー留置術 15 例の検討口頭発表（一般）
- 第47回日本外科系連合学会学術集会, 2022年06月, 日本語, 国内会議門脈腫瘍栓のみを認めた肝細胞癌に対して集学的治療が奏功した１例口頭発表（一般）
- 第47回日本外科系連合学会学術集会, 2022年06月, 日本語, 国内会議粒子線治療を目的とした仙骨脊索腫に対する吸収性スペーサー留置術の経験口頭発表（招待・特別）
- 第47回日本外科系連合学会学術集会, 2022年06月, 日本語, 国内会議腹部悪性腫瘍に対するネスキープ留置術の外科的経験シンポジウム・ワークショップパネル（公募）
- 第34回日本肝胆膵外科学会・学術集会, 2022年06月, 英語, 国内会議Impact of Delayed Gastric Emptying After Pancreatoduodenectomy on Postoperative Nutritional Statusポスター発表
- 第34回日本肝胆膵外科学会・学術集会, 2022年06月, 英語, 国内会議Spontaneous rupture of splenic hilar lymph node metastasis from hepatocellular carcinoma: a rare case reportポスター発表
- 第34回日本肝胆膵外科学会・学術集会, 2022年06月, 英語, 国内会議Laparoscopic anatomic liver resection of segment 2 based on the anatomical variation of the hepatic veinsポスター発表
- 第34回日本肝胆膵外科学会・学術集会, 2022年06月, 英語, 国内会議Low levels of C-reactive protein on postoperative day 1 are an early predictor for posthepatectomy liver failure in hepatocellular carcinoma patients undergoing right hepatectomyポスター発表
- 第34回日本肝胆膵外科学会・学術集会, 2022年06月, 英語, 国内会議Current role of atezolizumab plus bevacizumab therapy in the sequential treatment of unresectable hepatocellular carcinomaポスター発表
- 第34回日本肝胆膵外科学会・学術集会, 2022年06月, 英語, 国内会議Utility of plasma serum D-dimer for diagnosis of venous thromboembolism after hepatectomyポスター発表
- 第34回日本肝胆膵外科学会・学術集会, 2022年06月, 英語, 国内会議Efficacy analyses of neoadjuvant treatment for patients with “resectable” pancreatic ductal adenocarcinomaポスター発表
- 第34回日本肝胆膵外科学会・学術集会, 2022年06月, 英語, 国内会議Laparoscopic Spleen Preserving Distal Pancreatectomy with Splenic Vessels Preservationポスター発表
- 第34回日本肝胆膵外科学会・学術集会, 2022年06月, 英語, 国内会議The usefulness of total tumor volume as a prognostic factor in patients with colorectal cancer liver metastasesシンポジウム・ワークショップパネル（公募）
- 第58回日本肝臓学会総会, 2022年06月, 日本語, 国内会議HCV関連肝癌切除例におけるDAA治療群とIFN治療群,非SVR群の比較検討ポスター発表
- 第58回日本肝臓学会総会, 2022年06月, 日本語, 国内会議肝細胞癌に対する肝切除における予後予測因子としてのサルコペニアの影響に関する観察研究口頭発表（一般）
- 第37回日本臨床栄養代謝学会学術集会, 2022年05月, 日本語, 国内会議膵癌における術前Retinol Binding Protein低値は予後不良因子であるシンポジウム・ワークショップパネル（公募）
- 第191回兵庫県外科医会学術集会, 2022年05月, 日本語, 国内会議横隔膜腹腔側に発生した solitary fibrous tumor の1例口頭発表（一般）
- Meet the Expert 膵癌外科手術と周術期管理～膵癌患者のoutcome向上を目指して～, 2022年05月, 日本語, 国内会議低侵襲膵癌手術と術後栄養療法口頭発表（一般）
- Meet the Expert 膵癌外科手術と周術期管理～膵癌患者のoutcome向上を目指して～, 2022年05月, 日本語, 国内会議パネルディスカッションシンポジウム・ワークショップパネル（公募）
- 第58回日本肝癌研究会, 2022年05月, 日本語, 国内会議内側アプローチによる腹腔鏡下尾状葉切除シンポジウム・ワークショップパネル（公募）
- SAGES 2022 Annual Meeting, 2022年03月, 英語, 国際会議Laparoscopic anatomic liver resection of segment 2 by glissonean approachポスター発表
- 第49回日本膵・膵島移植学会, 2022年03月, 日本語, 国内会議異種膵島移植実現に向けたGlycan arrayを用いた膵島異種抗原の解析シンポジウム・ワークショップパネル（公募）
- 日本消化器病学会近畿支部第116回例会, 2022年02月, 日本語, 国内会議膵中央切除後に多発残膵再発をきたし残膵全摘術を施行した膵胆道型(pancreatobiliary type）IPMCの1例口頭発表（一般）
- 第38回近畿肝移植検討会, 2021年12月, 日本語, 国内会議新型コロナ感染拡大が肝移植にもたらした影響と問題点口頭発表（一般）
- 第44回日本肝臓学会西部会, 2021年12月, 日本語, 国内会議肝移植後合併症に対する移植時年齢の及ぼす影響に関する検討口頭発表（一般）
- 第34回日本内視鏡外科学会総会, 2021年12月, 日本語, 国内会議腹腔鏡下膵頭十二指腸切除導入の経験口頭発表（一般）
- 第83回日本臨床外科学会総会, 2021年11月, 日本語, 国内会議門脈腫瘍栓を疑い門脈合併切除を施行した膿瘍形成・門脈血栓を伴うpT1a膵頭部癌の1例口頭発表（一般）
- 第83回日本臨床外科学会総会, 2021年11月, 日本語, 国内会議幽門側胃切除後の膵体尾部切除における残胃温存実現可能性の検討口頭発表（一般）
- American Pancreas Association2021 Annual meeting(APA 2021), 2021年11月, 英語, 国際会議Metabolic measures before surgery and long-term diabetes outcomes in recipients of total pancreatectomy and islet autotransplantation口頭発表（一般）
- 第57回日本胆道学会学術集会, 2021年10月, 日本語, 国内会議胆道癌におけるSystematic inflammation-based scoresの意義口頭発表（一般）
- 第52回日本膵臓学会大会, 2021年09月, 日本語, 国内会議膵神経内分泌腫瘍における血液バイオマーカーの検索シンポジウム・ワークショップパネル（公募）
- 第57回日本移植学会総会, 2021年09月, 日本語, 国内会議膵島移植の成績向上に向けて ー自家膵島移植の検討から見えてきたものー口頭発表（一般）
- 日本消化器病学会近畿支部第115回例会, 2021年09月, 日本語, 国内会議座長（Young Inverstigator session10)その他
- 第76回日本消化器外科学会総会, 2021年07月, 日本語, 国内会議膵神経内分泌腫瘍の予後予測因子に基づいた治療戦略口頭発表（一般）
- 第121回日本外科学会定期学術集会, 2021年04月, 日本語, 国内会議術前分枝鎖アミノ酸飲料の使用は肝胆膵外科手術中の乳酸産生を抑制するポスター発表
- 日本癌治療学会2021年 - 現在
- 日本臨床外科学会2021年 - 現在
- 日本胆道学会2021年 - 現在
- 日本肝臓学会2015年 - 現在
- 日本膵臓学会2013年 - 現在
- 日本消化器病学会2013年 - 現在
- 日本臨床代謝栄養学会2012年 - 現在
- 日本肝胆膵外科学会2012年 - 現在
- 日本内視鏡外科学会2011年 - 現在
- 日本消化器外科学会2010年 - 現在
- 日本外科学会2007年 - 現在
- 日本学術振興会, 科学研究費助成事業, 基盤研究(B), 神戸大学, 2024年04月 - 2028年03月, 研究分担者iPS 細胞由来の膵島と血管新生誘導ゲルを組み合わせた血管形成機構の構築
- 日本学術振興会, 科学研究費助成事業, 若手研究, 神戸大学, 2024年04月 - 2026年03月, 研究代表者膵頭十二指腸切除術後の脂質異常症の病態メカニズムの解明
- 公益財団法人神戸医療産業都市推進機構, 神戸医療産業都市研究開発補助金, 2023年04月 - 2026年03月, 研究分担者バイオ人工膵島用新規移植デバイスの開発
- 日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 2023年04月 - 2026年03月, 研究分担者新規血管新生促進剤を応用した「バイオ人工膵島」移植の確立1.アルギン酸カプセルのセットアップと特性解析 (新規カプセル製造法の確立) (1) 幼若ブタからの膵島分離：カプセル化膵島（バイオ人工膵島と呼称）作製にラット由来膵島を用いる予定であったが、性能評価に大量の膵島が必要であるため、2週齢の幼若ブタ（ZPP）由来膵島を用いて実験を行った。これまでに膵島分離を4回行い、1膵臓当たりの膵島収量は、1回目: 304,305IEQ、2回目: 85,213IEQ、3回目: 881,320 IEQ、4回目: 3,329IEQであった。 (2) 分離膵島のアルギン酸カプセルへの新規包埋技術の確立：バイオ人工膵島の従来製造法では、カプセル粒径が大きく不均一（600-1,000μm）になるという実用化に向けての決定的な課題が存在した。本研究では、① 電界紡糸装置、② バイオ３Dプリンターを導入し、新規カプセル製造法の開発に着手した。予備実験において、各々のカプセル平均粒径は、① 393μm、② 531μmであり、従来製造法と比較し粒径の小型化・均一化を達成した。 2.皮下移植法の確立 (1) 血管新生促進剤（神戸大学オリジナル）の応用：研究分担者である大谷らは、ヒアルロン酸（HA）架橋ゲルに対してポリエチレングリコール（PEG：分子量6,000）を5質量%含有させ、ここにbFGFを2.5μg/gelとすると血管新生を誘導することを明らかにしている。予備実験として、8-12週齢C57BL/6の皮下に、① コントロール（PBS）、② HAゲル、③ bFGF、④ 5PEG/HAゲル、⑤ HAゲル+ bFGF、⑥ 5PEG/HAゲル+ bFGFを埋植したのち、埋植後14日目に埋植した皮下組織を切除し、血管内皮マーカーであるCD31で組織染色した。染色陽性域を比較検討したところ、⑤、⑥で血管新生の促進を認めた。
- 日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 2023年04月 - 2026年03月, 研究分担者膵及び十二指腸切除後のアミノ酸代謝の変化の解析と新規栄養療法の開発本研究では、膵切除前後におけるアミノ酸プロファイルの変化の解析、膵切除後脂肪肝と栄養障害およびアミノ酸代謝の変化の関係の解析、これらの知見をもとにした膵切除における新たな栄養療法開発を目的としている。解析対象として術前および術後３ヶ月の血液サンプルを収集する必要があるが、目標サンプル数150例に対し、現在約70例のサンプル収集が終了している。そのうち40例程度では、質量分析計にてアミノ酸を網羅的に解析しており、データを収集している。データ数が少ないため今のところ詳細な結果は出ていないが、膵切除における周術期の栄養状態について解析し、術前術後の低栄養、特にプレアルブミンの低下が短期のみならず長期成績や予後にも悪影響を及ぼすことを明らかにし、JDDW2023ワークショップにて報告した。今後約１年で150例のサンプル収集が終了しする予定で、並行してアミノ酸解析を進める予定である。また、現在膵切除後の脂肪肝について臨床例の解析を進めている。膵切除後のおよそ３０％程度に脂肪肝の発生を認めており、現在脂肪肝と膵切除後栄養障害、必須脂肪酸代謝の変化について解析を進めている。その結果、膵切除後の脂肪肝発生には低栄養状態、特に必須アミノ酸の低下の関連が示唆されるデータを得ており、引き続き臨床データを収集し、脂肪肝発生と栄養障害、特に脂質代謝とアミノ酸代謝の関係を解析する予定である。新たな栄養療法の開発についてはまだ十分な根拠がなく、今後栄養やアミノ酸代謝の解析をもとに開発を進めていく予定である。
- 国立研究開発法人医薬基盤・健康・栄養研究所, 希少疾病用再生医療品等開発支援事業, 2022年 - 2026年, 研究分担者1型糖尿病に対する皮下血管新生促進技術を応用した「バイオ人工膵島」移植治療の開発
- 認定特定非営利活動法人日本IDDMネットワーク, 1型糖尿病研究基金, 2023年04月 - 2024年03月, 研究分担者移植用膵島の「量産化」技術の開発
- 日本学術振興会, 科学研究費助成事業 若手研究, 若手研究, 神戸大学, 2021年04月 - 2024年03月, 研究代表者膵頭十二指腸切除後の脂質吸収と脂質代謝異常の解明
- 認定特定非営利活動法人日本IDDMネットワーク, 1型糖尿病研究基金, 2022年04月 - 2023年03月, 研究分担者インスリン離脱ができる異種膵島移植法の確立と産業化に向けた生産システムの構築